[go: up one dir, main page]

WO2025096781A1 - Méthodes et compositions pour fournir des régimes cutanés personnalisés - Google Patents

Méthodes et compositions pour fournir des régimes cutanés personnalisés Download PDF

Info

Publication number
WO2025096781A1
WO2025096781A1 PCT/US2024/053891 US2024053891W WO2025096781A1 WO 2025096781 A1 WO2025096781 A1 WO 2025096781A1 US 2024053891 W US2024053891 W US 2024053891W WO 2025096781 A1 WO2025096781 A1 WO 2025096781A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
vitamin
subject
acid
category
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/053891
Other languages
English (en)
Other versions
WO2025096781A8 (fr
Inventor
Hari Krishnan KRISHNAMURTHY
Vasanth JAYARAMAN
Kang BEI
Tianhao WANG
John J. Rajasekaran
Deborah JEYASEKAR
Hannah RAJASEKARAN
Karthik Krishna
Karenah RAJASEKARAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vibrant Holdings LLC
Original Assignee
Vibrant Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vibrant Holdings LLC filed Critical Vibrant Holdings LLC
Publication of WO2025096781A1 publication Critical patent/WO2025096781A1/fr
Publication of WO2025096781A8 publication Critical patent/WO2025096781A8/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0077—Devices for viewing the surface of the body, e.g. camera, magnifying lens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235—Details of waveform analysis
    • A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • Flawless skin is universally desired by people, as they are constantly on the quest to find the “best” skin products to achieve even-toned, clear, and radiant skin. This has led to an exponential rise of unverified advice or products to achieve good skin in the market.
  • a person’s skin health is dependent on factors such as susceptibility to skin irritants, allergies, immune function, genetic makeup, oxidative stress, collagen degradation, elastin degradation, and a variety of other factors.
  • Commercial products have been created and developed to address common skin concerns such as pigmentation, acne, wrinkling, skin sagging, skin aging, etc., that correlate to the numerous skin health factors.
  • commercially available skin care products have attempted to cater to different skin types, these products generally lack the ability to improve the skin on personal level.
  • customized skin regimens that can help improve an individual’s skin health based on a particular individual’s skin profile.
  • Such customized skin regimen can effectively provide personalized skin products, dietary, supplement, and lifestyle suggestions along with routine monitoring strategies in accordance an individual’s skin profile.
  • methods for determining quantities of each active element to be included in the customized skin regimens are disclosed herein.
  • a method for determining a customized skin regimen for a subject comprising:
  • a method for determining a customized skin regimen for a subject comprising: for one or more skin activity categories, each skin activity category comprising a plurality of elements being considered for inclusion in the customized skin regimen: i. obtaining or having obtained one or more of: genetic statuses of one or more genomic locations related to the skin activity category from one or more samples obtained from the subject; methylation statuses of one or more genes involved in biological processes of the skin activity category; and an image captured of the subject’s skin; ii.determining a methylation score, a phenotype score, and a genetic score for the skin activity category for the subject using the one or more of genetic statuses, methylation statuses, and the image; iii.for each of one or more of the methylation score, phenotype score, and genetic score, determining a fixed value for each of the plurality of elements of the skin activity category using the corresponding score; iv.for each element of the plurality of elements, combining fixed values across the one or
  • the one or more skin activity categories comprise an antiaging and wrinkle reduction category, a lymphatic drainage category, a skin firming and elasticity category, a brightening and pigmentation category, a UV/oxidative damage/DNA/cell damage category, an anti-inflammatory and soothing category, and a hydration and skin barrier repair category.
  • determining the methylation score for the skin activity category for the subject comprises combining methylation levels of one or more genes in the skin activity category.
  • the skin activity category is the anti-aging and wrinkle reduction category, and wherein the one or more genes include one or more of CDKN2A, COL1A1, MMP1, and SIRT.
  • the skin activity category is the lymphatic drainage category and wherein the one or more genes include one or more of NFAT5, VEGFC, and PROXI. In various embodiments, the skin activity category is the skin firming and elasticity category and wherein the one or more genes include one or more of ELN, KLF4, and WRN. In various embodiments, the skin activity category is the brightening and pigmentation category and wherein the one or more genes include one or more of IGF2 and TYR. In various embodiments, the skin activity category is the UV/oxidative damage/DNA/cell damage category and wherein the one or more genes include one or more of TP53, BCL2, and SYN1.
  • the skin activity category is the anti-inflammatory and soothing category and wherein the one or more genes include one or more of TNF-a, CSCL8, and IL- 6.
  • the skin activity category is the hydration and skin barrier repair category and wherein the one or more genes include one or more of FILAGGRIN (FLG), TGM1, CSCL8, CLDN1, and AQP3.
  • determining the phenotype score further comprises determining a second value based on answers included on a skin questionnaire including a set of questions related to the skin activity category.
  • the phenotype score for the skin activity category comprises combining the one or more values determined by analyzing the image and the second value determined based on answers included on the skin questionnaire.
  • determining the phenotype score further comprises mapping the combined one or more values and the second value to the phenotype score.
  • determining the genetic score comprises determining a quantity of genetic issues in the subject.
  • the quantity of genetic issues comprises one or more genetic statuses indicative of a mutation.
  • determining a fixed value for each of the plurality of elements comprises accessing a look up table. In various embodiments, at least two of the plurality of elements have different determined fixed values. In various embodiments, combining fixed values across the one or more of the methylation score, phenotype score, and genetic score comprises determining an average of fixed values of the methylation score and the phenotype score. In various embodiments, combining fixed values across the one or more of the methylation score, phenotype score, and genetic score further comprises summating the determined average of fixed values of the methylation score and the phenotype score and a fixed value of the genetic score.
  • the one or more of peptides for the anti-aging and wrinkle reduction category comprise one or more of palmitoyl pentapeptide- 3 (Matrixyl), acetyl dipeptide- 1 cetyl ester (Idealift), acetyl hexapeptide-8 (Argireline), acetyl hexapeptide-30 (Inyline®-Peptide), acetyl hexapeptide-51 amide (Juveleven), Argirelox (Pentapeptide 18+Argireline), SNAP 8-acetyl octapeptide- 3, Tripeptide 5, GHK Cu, ReproageTM, Synake, or palmitoyl pentapeptide 38.
  • palmitoyl pentapeptide- 3 palmitoyl pentapeptide- 3
  • acetyl dipeptide- 1 cetyl ester Idealift
  • acetyl hexapeptide-8 acetyl
  • the one or more of peptides for the lymphatic drainage category comprise eyeseryl-acetyl tetrapeptide-5.
  • the one or more of peptides for the skin firming and elasticity category comprise one or more of palmitoyl hexapeptide- 12 (Biopeptide EL), palmitoyl oligopeptide (Bio-bustyl), myristoyl pentapeptide- 8 (SymPeptide 225), palmitoyl oligopeptide (Biopeptide CL), acetyl heptapeptide 4 (Fensebiome), triptide- 10 citrulline (Decorinyl), hexapeptide- 10 (Serilesine), acetyl tetrapeptide- 11 (Syniorage), acetyl hexapeptide-38 (Adifyline), hexapeptide- 11 (Peptide Vinci 2), acetyl dipeptide-13 diphenylglycine (Relistase), palmitoyl dipeptide-5 diaminobutyloyl hydroxy
  • the one or more of peptides for the hydration and skin barrier repair category comprise one or more of Decapeptide-4, acetyl hexapeptide-37 (Diffuporine), Oligopeptide-24 (EGF-like peptide), FSS Ceramide 3, sodium pea, or APT-GPF.
  • the one or more of peptides for the anti-inflammatory and soothing category comprise one or more of acetyl hexapeptide-49 (Delisens), palmitoyl tetrapeptide-7, acetyl tetrapeptide- 15 (Skinasensyl), polyquaternium-51, allantoin, hesperdine methyl chaicone, acetyl tetrapeptide-40 (TELANGYN), acetyl dipeptide-3 aminohexanoate (Bodyfensine), Oligopeptide- 10, or Acetyl Tetrapeptide-2 (Syn-UP).
  • the one or more of peptides for the brightening and pigmentation category comprise one or more of Hexapeptide-2, Nonapeptide- 1 (Melanostatine), Decapeptide 12, Oligopeptide-34, or Oligopeptide-51.
  • the one or more of peptides for the UV/Oxidative Damage/DNA/Cell damage category comprise one or more of DAP tripeptide 33, pepha tight, ferulic acid, acetyl tetrapeptide-22 (Thermostressine), acetyl heptapeptide- 1, or tripeptide-9 citrulline (dGlyage).
  • the customized skin regimen further comprises one or more prebio tic and probiotic.
  • the one or more prebiotic and probiotic comprise one or more of Pepha active, beta glucan, Bacillus extract, sea kelp extract, or alpaflor sebum.
  • the customized skin regimen further comprises one or more vitamins.
  • the one or more vitamins comprises one or more of D- Panthenol, magnesium ascorbyl phosphate, tocopherols, or niacinamide.
  • the customized skin regimen further comprises one or more base elements.
  • the method further comprises: i.obtaining or having obtained levels of a plurality of skin biomarkers from one or more samples obtained from the subject; ii. obtaining or having genetic statuses of one or more genomic locations of a plurality of genes from the one or more samples obtained from the subject; and iii.determining the customized skin regimen for the subject using both the levels of the plurality of skin biomarkers and the genetic statuses of one or more genomic locations of a plurality of genes.
  • the skin biomarkers comprise one or more of collagens and elastins obtained from serum of the subject.
  • the collagen biomarkers comprise one or more of aminoterminal propeptide of Collagen 1 (PINP), carboxy-terminal propeptide of type 1 collagen (PICP), crosslinked telopeptide of type 1 collagen (ICTP), amino-terminal propeptide of collagen 3 (PIIINP), matrix metalloproteinases- 1 (MMP-1), tumor necrosis factor-alpha (TNF-a), insulin-like growth factor-1 (IGF-1), or basic fibroblast growth factor (FGF-2).
  • the elastin biomarkers comprise one or more of matrix metalloproteinases- 12 (MMP-12) or elastin-derived peptides (EDPs).
  • the serum is collected using one or more of ethylenediaminetetraacetic acid (EDTA), serum separator tube (SST), dried blood spot, or ficoll tube.
  • EDTA ethylenediaminetetraacetic acid
  • SST serum separator tube
  • dried blood spot or ficoll tube.
  • the levels of the plurality of skin biomarkers are obtained by using one or more of microarray or mass spectrometry.
  • the skin biomarkers comprise one or more lipids obtained from sebum of the subject.
  • the sebum is obtained using an absorbent medium or material.
  • the one or more lipids comprise one or more of glycerol lipids, free fatty acids, or cholesterol.
  • the skin biomarkers from the one or more samples obtained from the subject comprise skin biomarkers from urine of the subject.
  • the skin biomarkers from urine of the subject comprise one or more UV damage metabolites and oxidative stress loads from the urine of the subject.
  • the skin biomarkers comprise one or more advanced glycation end products from urine or blood of the subject.
  • the advanced glycation end products comprise one or more of carboxymethyl lysine (CEL), carboxymethyl lysine (CML), glucosepane, or pentosidine.
  • CEL carboxymethyl lysine
  • CML carboxymethyl lysine
  • glucosepane glucosepane
  • pentosidine pentosidine
  • the skin biomarkers comprise one or more microorganisms from skin niches of the subject.
  • the microorganisms comprise one or more of Propionibacterium acnes, Propionibacterium avidum, or Propionibacterium granulosum, optionally from forehead of the subject.
  • the microorganisms comprise Propionibacterium acnes, optionally from cheek of the subject.
  • the microorganisms comprise one or more of Staphylococcus epidermidis, Corynebacterium spp, or Propionibacterium acnes, optionally from nasolabial fold of the subject.
  • the microorganisms comprise Propionibacterium acnes, optionally from chin of the subject.
  • the microorganisms comprise Firmicutes, optionally from face of the subject.
  • the microorganisms comprise one or more of Corynebacterium kroppenstedtiin or Staphylococcus epidermidis, optionally from cheek of the subject.
  • the microorganisms comprise Corynebacterium kroppenstedtiin, optionally from nasolabial fold of the subject.
  • the microorganisms comprise Staphylococcus epidermidis, optionally from eyelid of the subject. [0043] In some embodiments, the microorganisms comprise Staphylococcus epidermidis, optionally from cheek of the subject.
  • the microorganisms comprise Corynebacterium species, optionally from chin of the subject.
  • the microorganisms comprise Malassezia spp, optionally from cheek of the subject.
  • the microorganisms comprise one or more Eikenella corrodens, Cutibacterium, Micrococcus luteus, or Kocuria, optionally from cheek of the subject.
  • the microorganisms comprise Corynebacterium, optionally from cheek of the subject.
  • the microorganisms comprise one or more of Corynebacterium amycolatum, Proteobacteria, Firmicutes, Bacteroidetes, or Propionibacterium, optionally from forehead of the subject.
  • the microorganisms comprise Propionibacterium, optionally from cheek of the subject.
  • the microorganisms comprise one or more of Corynebacterium, Lactobacillus, or Cutibacterium, optionally from face of the subject.
  • obtaining the levels of a plurality of skin biomarkers further comprises determining one or more combinations of levels of the one or more hormones.
  • determining one or more combinations of levels of the one or more hormones comprises determining one or more of Estriol (E3)/(E1+E2), 2-OH (El + E2)/16a-OH El, 2-MeO E1/2-0H El, 4-MeO E1/4-0H El, 4-MeO E2/4-OH E2, testosterone (T)/Epi-T, b-pregnanediol/E2, cortisol/cortisone, or metabolized cortisol (THF+THE), or Prostaglandin (Pg)/E2.
  • the hormones comprise one or more of estrone (El), estradiol (E2), Estriol (E3), total estrogen, 2-OH estradiol, 2-OH estrone, 4-OH estradiol, 4-OH estrone, dehydroepiandrosterone (DHEA), androstenedione, androsterone, etiocholanolone, 5-alpha- dihydrotestosterone (5a-DHT), 5a, 3a- Androstanediol, 5P-Androstanediol, dehydroepiandrosterone sulfate (DHEA-S), progesterone, allopregnanolone, allopregnanediol, 3a-dihydroprogesterone, 20a- dihydroprogesterone, b-pregnanediol, a-pregnanediol, cortisol, cort
  • obtaining the levels of a plurality of skin biomarkers further comprises determining one or more combinations of levels of the one or more hormones.
  • determining one or more combinations of levels of the one or more hormones comprises determining one or more of E3/(E1+E2), 2-OH (El + E2)/16a-OH El, 2-MeO E1/2-OH El, 4-MeO E1/4-OH El, 4-MeO E2/4-OH E2, T/Epi-T, b- pregnanediol/E2, cortisol/cortisone, or metabolized cortisol (THF+THE), or Prostaglandin (Pg)/E2.
  • the skin biomarkers comprise one or more metabolism markers from serum or urine of the subject.
  • the metabolism markers comprise one or more serum metabolism biomarkers.
  • the serum metabolism biomarkers comprise one or more of lipid metabolism biomarkers, carbohydrate metabolism biomarkers, or cellular biomarkers.
  • the lipid metabolism biomarkers comprise one or more of vaccenic acid, adiponectin, acylhexosylceramide (AHC), diacylglycerol (DAG), dimethylphosphatidy lethanolamine (DMPE), or plasminogen activator inhibitor- 1 (PAI-1).
  • the carbohydrate metabolism biomarkers comprise one or more of adiponectin, gastric-inhibitor-peptide (GIP), or leptin.
  • GIP gastric-inhibitor-peptide
  • the cellular biomarkers comprise nicotinamide adenine dinucleotide (NAD).
  • NAD nicotinamide adenine dinucleotide
  • the metabolism markers comprise one or more urine metabolism biomarkers.
  • the urine metabolism biomarkers comprise one or more of lipid metabolism biomarkers or carbohydrate metabolism biomarkers.
  • the lipid metabolism biomarkers comprise one or more of adipate, suberate, or ethyl malonate.
  • the carbohydrate metabolism biomarkers comprise one or more of pyruvate, L-lactate, or P-hydroxybutyrate.
  • the nutrients comprise one or more vitamins or minerals.
  • the vitamins or minerals comprise one or more of Folate (L-5- methyltetrahydrofolate), magnesium, iron, vitamin A (retinol), vitamin D3 (choice alciferol), vitamin E, choline, free Carnitine, vitamin Bl (thiamine diphosphate), vitamin B2 (riboflavin 5-Phosphate), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxal 5-Phosphate), vitamin C (L-ascorbic acid), copper, zinc, selenium, chromium, or manganese.
  • Folate L-5- methyltetrahydrofolate
  • magnesium iron
  • iron iron
  • vitamin A retinol
  • vitamin D3 choice alciferol
  • vitamin E choline
  • free Carnitine free Carnitine
  • vitamin Bl thiamine diphosphate
  • vitamin B2 riboflavin 5-Phosphate
  • vitamin B5 pantothenic acid
  • vitamin B6 pyridoxal 5-Phos
  • the nutrients comprise one or more vitamins and minerals, amino acids, or fatty acids.
  • the method further comprises further comprising determining one or more combinations of levels of one or more of the vitamins and minerals.
  • determining one or more combinations of levels of one or more of the vitamins and minerals further comprises obtaining a ratio of copper/zinc.
  • the amino acids comprise one or more of glutathione (oxidized), methylmalonic acid (MMA), choline, L-cysteine, L-asparagine, L-glutamine, L- serine, L-arginine, L-citrulline, L-isoleucine, L-valine, L-leucine, free carnitine, or phenylalanine.
  • the fatty acids comprise one or more of docosahexaenoic acid (DHA), Eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), arachidonic acid (AA), or linoleic acid (LA).
  • DHA docosahexaenoic acid
  • EPA Eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • AA arachidonic acid
  • LA linoleic acid
  • the method further comprises obtaining the levels of a plurality of skin biomarkers by determining one or more combinations of levels of one or more of the fatty acids.
  • determining one or more combinations of levels of one or more of the fatty acids further comprises obtaining omega-3 total, omega-6 total, omega-3 index, or a ratio of AA/EPA.
  • the skin biomarkers comprise one or more commensal microorganisms from the subject.
  • the commensal microorganisms comprise one or more of commensal bacteria, archaea, fungi, or viruses.
  • the skin biomarkers further comprise gut metabolites from the subject.
  • the method further comprises obtaining or having obtained one or more demographics of the subject; and determining the customized skin regimen for the subject based on the demographics of the subject.
  • the demographics comprise one or more of an age or gender of the subject.
  • the method further comprises: i. obtaining or having obtained an image of a face from the subject; ii. grading severities of one or more phenotypic parameters for the face of the subject based on the image; and iii. determining the customized skin regimen for the subject based on the severity of the one or more phenotypic parameters.
  • the phenotypic parameters comprise one or more of wrinkles, periorbital-around eyes (puffy eyes), nasolabial folds (laugh lines), worry lines, uneven skin tone/pigmentation, or age spots (liver spots).
  • the method further comprises obtaining or having obtained answers to a skin questionnaire from the subject; and determining the customized skin regimen for the subject based on the answers from the subject.
  • the questionnaire comprises one or more questions related to skin goals, type of skin, sun exposure, or skin proneness to external factors.
  • the method further comprises administering the customized skin regimen to the subject.
  • customized skin regimens wherein the customized skin regimen is determined according to a method disclosed herein.
  • a skin biomarker is the Amino terminal propeptide of Collagen 1 (PINP), and the composition comprises one or more of vitamin C, peptides, retinoids, copper peptides, copper, collagen or collagen peptides, and/or omega-3 fatty acids;
  • a skin biomarker is the Carboxy terminal propeptide of type 1 collagen (PICP) and the composition comprises one or more of hyaluronic acids, retinoids, vitamin C, niacinamide, collagen or collagen peptides, zinc, and/or omega-3 fatty acids; iii.
  • a skin biomarker is the Matrix metalloproteinase- 1 (MMP-1) and composition comprises one or more of ginseng, green tea extract, retinoids, vitamin C, peptides, collagen or collagen peptides, vitamin E, vitamin C, and/or omega-3 fatty acids;
  • a skin biomarker is Insulin like growth factor- 1 (IGF-1) and the composition comprises one or more of capsaicin, vitamin C, hyaluronic acid, zinc, vitamin C, probiotics, collagen or collagen peptides, and/or omega-3 fatty acids; vii.
  • a skin biomarker is Basic fibroblast growth factor (FGF-2) and the composition comprises one or more of ginseng, vitamin C, hyaluronic acid, collagen or collagen peptides, resveratrol, glycine, and/or proline; viii. a skin biomarker is Matrix Metalloproteinase- 12 (MMP-12) and the composition comprises one or more of vitamin C, green tea extract, silicon, ginseng, and/or vitamin E; ix. a skin biomarker is Elastin derived peptides (EDPs), and the composition comprises one or more of niacinamide, hyaluronic acid, silicon, vitamin A, and/or aloe vera.
  • FGF-2 Basic fibroblast growth factor
  • FGF-2 Basic fibroblast growth factor
  • the composition comprises one or more of ginseng, vitamin C, hyaluronic acid, collagen or collagen peptides, resveratrol, glycine, and/or proline
  • the retinoid is one or more of retinol, retinal, tretinoin (retinoic acid), isotretinoin, alitretinoin, adapalene, bexarotene, tazarotene, and/or Trifarotene.
  • the Alpha hydroxy acid is one or more of glycolic acid, lactic acid, mandelic acid, and/or citric acid.
  • a polymorphism is a SNP associated with melanin synthesis and the composition comprises one or more of Hydroquinone, Retinoids, Azelaic acid, Kojic acid, Cysteamine, Lignin peroxidase, Niacinamide, Ellagic acid, L- Cystine, L-Glutathione, Polypodium leucotomos, Melatonin, Arbutin, and/or Vitamin C; ii.
  • a polymorphism is a SNP associated with Moisturization and the composition comprises one or more of Vitamin E, Coenzyme Q10, Vitamin F, Kumazasa extract, Magnesium ascorbyl phosphate, Hyaluronic acid, Magnesium oil, collagen, ceramides, hyaluronan, procyanidin, probiotics, Galactooligosaccharides, Alpha-linolenic acid, and/or Gamma-linolenic acid; iii.
  • a polymorphism is a SNP associated with Skin Inflammation and the composition comprises one or more of Coenzyme Q10, Methylsulfonylmethane, Retinoid, Vitamin E, Vitamin C, Curcumin, Green tea or green tea extract, and/or Omega 3 fatty acids;
  • apolymorphism is a SNP associated with Melanocyte damage and the composition comprises one or more of Coenzyme Q10, Methylsulfonylmethane, Retinoid, Vitamin E, Vitamin D, Zinc, Vitamin C, Curcumin, Green tea or green tea extract, and/or Omega 3 fatty acids;
  • a polymorphism is a SNP associated with Collagen degradation and the composition comprises one or more of Retinoids, Vitamin C, Vitamin E, Tretinoin, Collagen peptides, Red ginseng, Aloe vera extract, Hyaluronic acid, Ginkgo biloba, and/or Soy; vi. a polymorphism is a SNP associated with Elastin synthesis and the composition comprises one or more of Retinoid, Vitamin C, Collagen or collagen peptides, Hyaluronic acid, Dexpanthenol, Vitamin E, Vitamin A, and/or Zinc; vii.
  • a polymorphism is a SNP associated with Antioxidants and the composition comprises one or more of Vitamin C, Coenzyme Q10, Polyphenols, Vitamin E, Curcumin, Vitamin C, Vitamin E, Beta carotene, Flavanols, zinc, Lutein, Lycopene, Silymarin, and/or Green tea or green tea extract; viii.
  • a polymorphism is a SNP associated with Vitamin A deficiency and the composition comprises one or more of Retinol, Vitamin E, Resveratrol, Baicalin, B-vitamins, Vitamin C, Epigallocatechin gallate, Collagen, Nicotinamide riboside, Nicotinamide mononucleotide, Coenzyme Q10, and/or Curcumin; ix.
  • a polymorphism is a SNP associated with Vitamin B6 deficiency and the composition comprises one or more of B-vitamins, Vitamin B6, Coenzyme Q10, Methylsulfonylmethane; Retinoids, and Vitamin E, Curcumin, Green tea or green tea extract, Omega 3 fatty acids, and/or Vitamin C; x.
  • a polymorphism is a SNP associated with Vitamin B 12 deficiency and the composition comprises one or more of Retinol, Vitamin E, Resveratrol, Baicalin, B-vitamins, Vitamin B12, Vitamin C, Curcumin, Epigallocatechin gallate, Collagen, Nicotinamide riboside, Nicotinamide mononucleotide, and/or Coenzyme Q10,; xi.
  • a polymorphism is a SNP associated with Vitamin C deficiency and the composition comprises one or more of Vitamin C, Coenzyme Q10, Polyphenols, Vitamin E, Curcumin, Beta carotene, Flavanols, zinc, Lutein, Lycopene, Silymarin, and/or Green tea or green tea extract; xii.
  • a polymorphism is a SNP associated with Vitamin D deficiency and the composition comprises one or more of Vitamin D, Retinol, Vitamin E, Resveratrol, Baicalin, B-vitamins, Vitamin C, Curcumin, Epigallocatechin gallate, Collagen, Nicotinamide riboside, Nicotinamide mononucleotide, and/or Coenzyme Q10; xiii.
  • a polymorphism is a SNP associated with Folate deficiency and the composition comprises one or more of Folate, Retinol, Vitamin E, Resveratrol, Baicalin, B-vitamins, Vitamin C, Curcumin, Epigallocatechin gallate, Collagen, Nicotinamide riboside, Nicotinamide mononucleotide, and Coenzyme Q10; and/or xiv.
  • a polymorphism is a SNP associated with Omega fatty acid deficiency and the composition comprises one or more of DHA (Docosahexaenoic acid), EPA, Coenzyme Al, Methylsulfonylmethane, Retinoid, Curcumin, Green tea or green tea extract and/or Vitamin E.
  • DHA Docosahexaenoic acid
  • EPA Docosahexaenoic acid
  • Coenzyme Al Methylsulfonylmethane
  • Retinoid Curcumin
  • Curcumin Green tea or green tea extract and/or Vitamin E.
  • a phenotypic parameter is wrinkles, Periorbital- around eyes (puffy eyes), Nasolabial folds (Laugh lines), worry lines, Uneven Skin tone/Pigmentation, and/or Age spots (Liver spots) and the composition comprises one or more of Tretinoin, Zeaxanthin, Retinol, Retinoids, Vitamin C, Hyaluronic acid, Caffeine, Phytonadione, Vitamin E, Astaxanthin, Hyaluronic acid, Peptides, Niacinamide, Azelaic acid, Soybean extract, Kojic acid, Aloesin, and/or Turmeric.
  • the customized skin regimen further comprises one or more of Zeaxanthin, Collagen, Vitamin C, Resveratrol, Vitamin E, Vitamin C, Hyaluronic acid, Glutathione, Niacinamide, and/or Coenzyme Q10.
  • a skin questionnaire question is: i. UV and the composition comprises one or more of Zinc oxide, titanium oxide, Polypodium leucotomos, Vitamin E, Vitamin C, and/or Niacinamide; ii. Anti-wrinkling and the composition comprises one or more of Tretinoin, Zeaxanthin, Retinol, Vitamin C, Hyaluronic acid, Collagen, Resveratrol, and/or Vitamin E; iii. Anti-pigmentation and the composition comprises one or more of Niacinamide, Azelaic acid, Vitamin C, Soybean extract, Retinoids, Kojic acid, Vitamin E, Aloesin, Turmeric, and/or Glutathione iv.
  • a hormone is: i. one or more of estrone (El), estradiol (E2), dehydroepiandrosterone (DHEA), testosterone, epi-testosterone (Epi-T), androstenedione (AD), androsterone, etiocholanolone, 5-alpha- dihydrotestosterone (5a-DHT), dehydroepiandrosterone sulfate (DHEA-S), progesterone (P), cortisol, cortisone, b-tetrahydrocortisol (b-THF), a-Tetrahydrocortisol (a-THF), b- Tetrahydrocortisone (b-THE), deoxycorticosterone, corticosterone, melatonin, or 8-hydroxy-2' -deoxyguanosine (8-OHdG); or ii.
  • estrone El
  • estradiol E2
  • DHEA dehydr
  • estrone El
  • estradiol E2
  • Estriol E3
  • total estrogen 2-OH estradiol
  • 2-OH estrone 4-OH estradiol
  • 4-OH estrone 4-OH estrone
  • dehydroepiandrosterone DHEA
  • etiocholanolone 5-alpha- dihydrotestosterone
  • 5a-DHT 5-alpha- dihydrotestosterone
  • DHEA- S dehydroepiandrosterone
  • progesterone progesterone
  • allopregnanolone allopregnanediol
  • 3a-dihydroprogesterone 20a-dihydroprogesterone
  • b-pregnanediol a-pregnanediol
  • cortisol cortisone
  • b-tetrahydrocortisol b-THF
  • the composition comprises one or more of Calcium D-glucarate, Green Tea, Maca DIM (3,3'-diindolylmethane), Black Cohosh, Ginger, Cranberry, Milk Thistle, Hops, Red clover, Damiana, Chaste Tree Berry Extract, Vitamin B2, Fenugreek seed, Ashwagandha, Vitamin D3, Zinc, Tribulus, Shatavari, Zinc, Shatavari, DHA, EPA, pine nuts, Licorice Root Extract, Oregano, Curcumin, Sodium, Rhodiola rosea, Vitamin B6, Vitamin B12, Magnesium, Folate, Iodine, Selenium, Potassium, Magnesium, Melatonin, Huang-qin, St. John's- wort, SAMe (S-adenosyl methionine), and/or Trimethylglycine (betaine).
  • Calcium D-glucarate Green Tea
  • Maca DIM 3,3'-diindolylmethane
  • a metabolic biomarker is one or more of Vaccenic acid, Adiponectin, Acylhexosylceramide (AHC), Dimethyl-phosphatidylethanolamine (DMPE), PAI-1, GIP, Leptin, NAD, Adipate, Suberate, Ethyl malonate, Pyruvate, L-lactate, and/or P- hydroxybutyrate and the supplemental or topical is one or more of Conjugated Linoleic Acid, DHA, EPA, Vitamin D, Curcumin, Berberine Extract, Resveratrol, Vitamin B3, Vitamin B6, Vitamin E, Choline, Vitamin C, Tryptophan, Nicotinamide riboside, Resveratrol, Quercetin, Vitamin B2, L-camitine, Vitamin Bl, Vitamin B12, CoQlO (Coenzyme Q10), Alpha lipoic acid, and/or Chromium.
  • Conjugated Linoleic Acid DHA, EPA, Vitamin D, Curcumin, Ber
  • the customized skin regimen further comprises an excipient or carrier.
  • the excipient or carrier is one or more of water, Caprylyl Glycol, butylene glycol, ultra low molecular weight (ulmw) hyaluronic acid, middle molecular weight (MMW) hyaluronic acid, and/or dimethyl isosorbide
  • customized skin regimens wherein the customized skin regimen comprises one or more supplement or topical medication, or a supplement and a topical medication.
  • the one or more topical medication and/or supplement comprise one or more of B-vitamins, Vitamin Bl, Vitamin B2, Vitamin B3, Vitamin B6, Vitamin B12, vitamin C, vitamin D, vitamin E, vitamin F, peptides, retinoids, copper peptides, copper, zinc, collagen or collagen peptides, omega-3 fatty acids, hyaluronic acids, niacinamide, zinc, proline, glycine, vitamin E, alpha hydroxy acids, ginseng, green tea or green tea extract, capsaicin, zinc, probiotics, resveratrol, glycine, proline, green tea or green tea extract, silicon, niacinamide, silicon, vitamin A, aloe vera, Hydroquinone, Azelaic acid, Kojic acid, Cysteamine, Lignin peroxidase, Ellagic acid, L-Cystine, L-Glutathione, Polypodium leucotomos, Melatonin,
  • the peptide is one or more of Hexapeptide- 11, GHK-Cu, Palmitoyl Pentapeptide-4 (Pal-KTTKS), Palmitoyl Tetrapeptide-7 (Pal-GQPR), Dipeptide-2, Palmitoyl Pentapeptide- 3, decapeptide- 12, Dipeptide Diaminobutyroyl Benzylamide Diacetate, Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine, Palmitoyl Dipeptide-5 Diaminohydroxybutyrate, Tetradecyl Aminobutyroylvalylaminobutyric Urea Trifluoroacetate, Acetyl Tetrapeptide-5, Heptapeptide-4, Acetyl Hexapeptide-51 Amide, Acetyl Hexapeptide-30, Acetyl Hexapeptide-8 (Argireline), acetyl hexapeptide-3 (Argireline), Acetyl
  • the retinoid is one or more of retinol, retinal, tretinoin (retinoic acid), isotretinoin, alitretinoin, adapalene, bexarotene, tazarotene, and/or Trifarotene.
  • the omega-3 fatty acid is one or more of Alpha-linolenic acid (ALA), Eicosapentaenoic acid (EPA), and/or Docosahexaenoic acid (DHA).
  • ALA Alpha-linolenic acid
  • EPA Eicosapentaenoic acid
  • DHA Docosahexaenoic acid
  • the Alpha hydroxy acid is one or more of glycolic acid, lactic acid, mandelic acid, and/or citric acid.
  • the customized skin regimen further comprises an excipient or carrier.
  • the excipient or carrier is one or more of water, Caprylyl Glycol, butylene glycol, ultra low molecular weight (ulmw) hyaluronic acid, middle molecular weight (MMW) hyaluronic acid, and/or dimethyl isosorbide.
  • FIG. 1 depicts a system overview for determining a customized skin regimen for an individual, in accordance with an embodiment.
  • FIG. 2A provides a diagram showing the information used to determine a customized skin regimen, in accordance with a first embodiment.
  • FIG. 2B provides a diagram showing the information used to determine a customized skin regimen, in accordance with a second embodiment.
  • FIG. 3 provides a flowchart of various exemplary methods for determining a customized skin regimen for an individual, in accordance with an embodiment.
  • FIG. 4 illustrates an example computing device for implementing system and methods described in FIGs. 1-3.
  • skin biomarkers refers to any biomarkers that indicate the skin health of a subject.
  • topical is a medication pertaining to the skin, such as a topical anti- infective agent applied to a certain area of skin and affecting only the area to which it is applied.
  • the topical or topical medication includes a large range of classes including creams, foams, gels, lotions, and ointments to treat ailments of the skin.
  • supply is a product taken to supplement a person’s diet.
  • skin product is any product intended to cleanse or beautify the skin. Depending on its purpose and effect, it can be cosmetics or medications.
  • ameliorating refers to any therapeutically beneficial result in the treatment of a disease state, e.g., a skin aliment, lessening in the severity or progression, remission, or cure thereof.
  • the term “sufficient amount” means an amount sufficient to produce a desired effect, e.g., an amount sufficient to change skin health condition of a subject.
  • the term “therapeutically effective amount” is an amount that is effective to ameliorate a symptom of a disease.
  • a therapeutically effective amount can be a “prophylactic ally effective amount” as prophylaxis can be considered therapy.
  • the phrase “obtaining or having obtained” encompasses the active step of obtaining certain information and/or a step of instructing e.g., a third party to obtain the information.
  • Exogenous or extrinsic factors affecting skin aging may include chronic light exposure, pollution, ionizing radiation, chemicals, toxins, and lifestyle factors (e.g., smoking, sleeping patterns, diet, and daily skincare habits).
  • Extrinsic skin aging is also referred to as photoaging with visible manifestations including coarse wrinkles, solar elastosis, pigment irregularities, etc. Contrary to intrinsic skin aging, extrinsic skin aging is characterized by prominent morphologic and physiologic changes and may result in premature aging of the skin. Extrinsic aging accounts for about 80% of visible skin aging with the signs superimposing the signs of intrinsic skin aging at chronically exposed areas of the body.
  • the sign of wrinkles in extrinsic skin aging or photoaging relates to the weakening bond between the dermis and epidermis, which may be caused by marked loss of fibrillin-positive structures and reduced content of collagen type VII (Col-7).
  • Col-7 collagen type VII
  • the distribution of collagen is altered in older skin with an increased ratio of Col-3 to Col-1.
  • Glycosaminoglycans (GAGs) the primary moisture-retaining dermal skin matrix constituents, may be associated with abnormal elastotic material and thus be unable to function effectively. Assessing these fundamental components may help with understanding the status of an individual’s skin.
  • Genetic polymorphisms influence genes that are involved in melanocyte pigmentation, skin tanning response, hydration, collagen and elastin synthesis, and skin inflammation, all of which are important factors affecting the skin. Therefore, assessing genetic polymorphisms is an important determinant of phenotypic variation.
  • Nutritional antioxidants including vitamin C, vitamin E, carotenoids, copper, and selenium may promote skin health by scavenging free radicals.
  • free radicals generated from endogenous metabolic pathways or exogenous factors may lead to oxidative stress, where the exogenous factors include at least exposure to UV radiation, ionizing radiation, pollution, alcohol intake, or smoking.
  • Oxidative stress results in the loss of functional characteristics and regenerative potential, exacerbating skin aging.
  • Sleep routine is another important factor affecting skin health since good sleep routines contribute to lower trans- epidermal water loss, better skin recovery, and lower intrinsic skin aging scores.
  • the present disclosure proposes methods and protocols that comprehensively assess skin health using skin-specific serum/urine biomarkers, genetic predispositions, and other various intrinsic and extrinsic aging factors to create personalized skin products and establish a personalized skincare regimen (including dietary and lifestyle interventions), thereby effectively improving an individual’s skin health.
  • the methods described herein measure and evaluate genetic, serum, and urine biomarkers that reflect the status of an individual’s skin health using a ‘Skin Plus’ panel. These markers are tested using various applicable microarray or mass-spectrometry techniques.
  • the test panel also assesses genetic polymorphisms that govern melanocyte pigmentation, skin tanning response, hydration, collagen and elastin synthesis, skin inflammation, etc.
  • genetic testing may be conducted using reverse transcription polymerase chain reaction.
  • the ‘Skin Panel’ can assess the status of the individual’s skin along with the genetic susceptibility to various skin aging factors.
  • a ‘Skin Health’ questionnaire is also designed to gauge the individual’s skin concerns, lifestyle factors, health comorbidities, and skincare goals.
  • the methods provided herein take the results from the biomarker and genetics tests along with the inferences from the questionnaire to establish a personalized skin regimen.
  • the methods may include creating personalized skin products, dietary and lifestyle suggestions, skincare suggestions, and recommendations for regular skin monitoring strategies.
  • the methods disclosed herein include further tests to comprehensively assess the individual’s intrinsic aging factors.
  • the methods disclosed herein apply ‘MetabolicPro’ and ‘HormonePro’ to test cellular metabolism and hormone health, respectively.
  • the present disclosure may also apply ‘NutriPro’ or ‘NutriLite’ tests to determine the influence of nutrient intake and nutrient deficiencies on the individual’s skin health.
  • the present disclosure may further assess the gut microbiome to determine how the gut affects the skin via the ‘gutskin axis’ . The results from these further tests also can be considered in designing the personalized skin regimen.
  • FIG. 1 further introduces a skin regimen system 130.
  • the skin regimen system 130 analyzes the various factors and determines a customized skin regimen 140 that is personalized for the individual 110.
  • Example compositions of customized skin regimens are disclosed herein.
  • the customized skin regimen is provided to the individual 110.
  • the individual 110 can self-apply the customized skin regimen e.g., topically.
  • FIG. 2A provides an overview of the various aspects of skin biomarker testing, genetic testing, and other tests provided by the method and compositions disclosed herein.
  • the present disclosure may carry out the following analysis and procedures: (1) skin serology (e.g., serological analysis for serum levels of collagen and elastin), (2) skin sebumetry (e.g., sebumetry analysis for skin lipids),
  • skin urology e.g., urine analysis for UV damage metabolites and oxidative stress load
  • skin genetics e.g., genetic analysis for skin parameters
  • methylation patterns e.g., genetic analysis for skin parameters
  • skin glycation e.g., genetic analysis for skin parameters
  • skin microbiome assessment e.g., genetic analysis for skin parameters
  • demographics e.g., demographics
  • phenotypic assessment e.g., experienced symptoms from the skin questionnaire
  • skin questionnaire information e.g., experienced symptoms from the skin questionnaire
  • additional tests including information regarding hormone levels, metabolism levels, nutrient levels, and gut microbiome.
  • the analysis and procedure of (1) skin serology generates data relating to serological skin biomarkers.
  • the analysis and procedure of (2) skin sebumetry generates data relating to sebum biomarkers.
  • the analysis and procedure of (3) skin urology generates data relating to urology biomarkers.
  • the analysis and procedure of (4) skin genetics generates data relating to genetic testing (e.g., genetic information relating to genetic statuses of one or more genomic locations).
  • FIG. 2B provides a diagram showing the information used to determine a customized skin regimen, in accordance with a second embodiment.
  • FIG. 2B shows a reduced number of analysis and procedures in comparison to those shown in FIG. 2A.
  • the analysis and procedures of FIG. 2B include (A) skin genetics (e.g., genetic analysis for skin parameters), (B) methylation patterns, (C) demographics, (D) phenotypic assessment, and (E) skin questionnaire information (e.g., experienced symptoms from the skin questionnaire).
  • kits for determining a level of skin biomarkers from serum of a subject i.e., serological skin biomarkers.
  • kits for providing a customized skin regimen based at least on the serological skin biomarkers of the subject comprising: obtaining or having obtained levels of a plurality of skin biomarkers from one or more samples obtained from the subject, and determining the customized skin regimen for the subject using at least the plurality of skin biomarkers, where the skin biomarkers are the serological skin biomarkers.
  • the serological skin biomarkers comprise one or more collagens and elastins.
  • the collagen biomarkers comprise one or more of amino-terminal propeptide of Collagen 1 (PINP), carboxy-terminal propeptide of type 1 collagen (PICP), crosslinked telopeptide of type 1 collagen (ICTP), amino-terminal propeptide of collagen 3 (PIIINP), matrix metalloproteinases- 1 (MMP-1), tumor necrosis factor-alpha (TNF-a), insulin-like growth factor-1 (IGF-1), or basic fibroblast growth factor (FGF-2).
  • the elastin biomarkers comprise one or more of matrix metalloproteinases- 12 (MMP-12) or elastin-derived peptides (EDPs).
  • Table 1 provides an exemplary set of serological markers that can be tested, along with their significance.
  • the collagen biomarkers are synthesis and degradation biomarkers, and the elastin biomarkers are degradation biomarkers.
  • determining a level of PINP can be used to improve collagen synthesis, and ICTP is measured to indicate collagen degradation, while MMP-12 and EDPs are tested to show the condition of skin elastin degradation.
  • Both the collagen biomarkers and the elastin biomarkers have the potential to enhance the assessment of skin statuses and inform personal decision-making in skin treatment.
  • the methods provided herein assess the levels of serological skin biomarkers in subject samples via any detection or collection method known in the art.
  • the detection methods include microarray and mass spectrometry.
  • the collection methods include ethylenediaminetetraacetic acid (EDTA), serum separator tube (SST), dried blood spot, or ficoll tube based methods.
  • EDTA ethylenediaminetetraacetic acid
  • SST serum separator tube
  • dried blood spot or ficoll tube based methods.
  • the methods provided herein evaluate the serological skin biomarkers and provide a customized skin regimen.
  • the skin regimen includes suggestions of both topicals and supplements for each serological marker being tested.
  • Table 2 shows exemplary suitable topical and supplement forms based on the testing of various serological markers.
  • a combination of topicals and/or supplements can be applied to improve skin health based on the determined levels of each serological biomarker. For example, based on the level of PINP tested for a specific subject, one or more of vitamin C, peptides, retinoids, and copper peptides may be applied on a particular area of the skin as topical medications, and one or more of collagen peptides, vitamin C, Omega-3 fatty acids, and copper can be used as daily supplements. Different types of topicals and supplements are used to improve different aspects of skin conditions based on different working mechanisms.
  • topical vitamin C can improve collagen synthesis and provide strength and structure to the skin, and topical peptides can strengthen the skin barrier, increase water retention, and stimulate collagen production, thereby improving the appearance of wrinkles in aging skin, while copper supplement can stimulate fibroblasts and collagen production and elastin fiber components, crosslink collagen, promote collagen fibril formation, and protect against oxidative damage.
  • the forms in the topical and/or supplement blend can be modified according to the individual’s other medications (e.g., genetic statuses as described below) when a customized skin regimen is given.
  • other medications e.g., genetic statuses as described below
  • determining a level of skin biomarkers from sebum of a subject i.e., sebum biomarkers.
  • kits for providing a customized skin regimen based at least on the sebum biomarkers of the subject comprising: obtaining or having obtained levels of a plurality of skin biomarkers from one or more samples obtained from the subject, and determining the customized skin regimen for the subject using at least the plurality of skin biomarkers.
  • the skin biomarkers comprise the sebum biomarkers, including one or more lipids obtained from sebum of the subject.
  • Sebum is the oily and waxy substance secreted by the sebaceous glands of the skin. It is a lipid-rich matrix, consisting of glycerolipids, free fatty acids, cholesterol, cholesterol esters, squalene, and wax esters. The component percentages of sebum are usually 30-50% glycerolipids, 15-30% free fatty acids, 1.5-2.5% cholesterol, 3-6% cholesterol esters, 12-20% squalene, and 26-30% wax esters. Alterations in the relative abundances of these sebum components are reflected by sebum biomarkers, which provide information about cutaneous diseases. Cutaneous diseases are conditions affecting the skin such as rashes, inflammation, itchiness, or other skin changes.
  • the measurement of sebum biomarkers is obtained using an absorbent medium or material. This measurement may help with quantifying the lipid concentration in a person’s sebum, thereby understanding the cause and severity of skin ailments (e.g., acne).
  • Urology biomarkers e.g., proteins/peptides
  • Urology biomarkers are substances that can be measured in urine to indicate the presence or progression of a urological condition. Urology biomarkers may help with skin health diagnosis, prognosis, and treatment. Skin urological biomarkers are currently being studied in clinical practice, which are used in combination with other tests and clinical findings to make a diagnosis or prognosis of skin health.
  • the urine analysis for UV damage metabolites and oxidative stress loads can be conducted in the methods disclosed herein.
  • the urology biomarkers of the subject comprise one or more of UV damage metabolites and oxidative stress loads from the urine of the subject.
  • methods for determining a customized skin regimen for a subject comprising: obtaining or having obtained levels of a plurality of skin biomarkers from one or more samples obtained from the subject; obtaining or having genetic statuses of one or more genomic locations of a plurality of genes from the one or more samples obtained from the subject; and determining the customized skin regimen for the subject using both the levels of the plurality of skin biomarkers and the genetic statuses of one or more genomic locations of a plurality of genes.
  • obtaining or having obtained genetic statuses of one or more genomic locations is based on determining deficiency predispositions at the genetic level (e.g., single nucleotide polymorphisms (SNPs), or other genetic mutations). Genetic testing for predispositions can assist in providing information about a subject’s skin health. Table 4 provides exemplary skin-related polymorphisms that can be assessed and the polygenic risk associated with the polymorphisms.
  • SNPs single nucleotide polymorphisms
  • genetic polymorphisms influence genes that are involved in melanocyte pigmentation, skin tanning response, hydration, collagen and elastin synthesis, and skin inflammation.
  • assessing genetic polymorphisms is an important determinant of phenotypic variation and skin disease susceptibility.
  • genes that can affect skin statuses There are various processes governed by specific genes that can affect skin statuses. Alterations in these genes may affect their normal functioning which can affect the skin statuses. These alterations can be assessed through genetic testing.
  • polymorphisms in the gene encoding may relate to water loss from the skin that gives rise to reduced skin moisturization capacity. Alterations in the BCM01 gene may show a vitamin A deficiency that accelerates the presence of wrinkles and ultimately skin aging.
  • Genetic testing can be carried out using any appropriate method known in the art, including but not limited to, reverse transcription polymerase chain reaction (RT-PCR) or quantitative-PCR (qPCR).
  • RT-PCR reverse transcription polymerase chain reaction
  • qPCR quantitative-PCR
  • the methods comprise obtaining or having obtained genetic information of the subject, the genetic information relating to melanin synthesis, moisturization, skin inflammation, melanocyte damage, collagen degradation, elastin synthesis, antioxidant, and nutritional needs.
  • the genetic information of the subject comprises genetic statuses of one or more genomic locations of a plurality of genes.
  • the genetic statuses comprise presence or absence of a polymorphism. In some embodiments, the genetic statuses comprise presence or absence of a polymorphism in a gene. In some embodiments, the genetic statuses comprise presence or absence of one or more polymorphisms. In some embodiments, the genetic statuses comprise presence or absence of one or more polymorphisms in one or more genes. In some embodiments, the genetic statuses comprise presence or absence of two, three, four, five, six, seven, eight, nine, ten, or more polymorphisms. In some embodiments, the one or more polymorphisms and/or genes are selected from Table 4.
  • the polymorphism is one or more of rs 1426654, rsl6891982, rsl042602, rsl393350, rs6058017, rs74653330, rsl393350, rsl805008, rsl015362, rs4911414, rsl2203592, rsl805007, rsl805009, rsl7553719, rs61816761, rsl38726443, rsl50597413, rs20541, rs2201841, rsl801133, rs610604, rsl7728338, rsl800795, rs4646994, rsl 169732, rsl799750, rs7787362, rsl001179, rsl050450, rsl800566, rs4880,
  • the plurality of genes comprises one or more of SLC24A5, SLC45A2, TYR, ASIP, OCA2, MC1R, IRF4, AQP3, FLG, IL-13, IL23R, MTHFR, TNFAIP3, TNIP1, IL-6, ACE, MMP9, MMP1, ELN1, CAT, GPX1, NOQI, SOD2, BCMO1, NBPF3, FUT2, SLC23A1, GC, MTHFR, or FADS1.
  • the effect of skin-related genetic predispositions can also be considered and addressed in the methods disclosed herein.
  • the effect of exemplary alleles for the respective exemplary skin-related genetic polymorphism provided in Table 4 can be determined by calculating a genotype value for each subject.
  • the genotype value can be determined based on the strength of each exemplary SNP that affects the nutrient levels in a subject. For example, risk genotypes can be assigned a higher or a lower score depending on the risk associated with a given SNP based on the effect of the SNP. For example, SNPs that are known to have more pronounced deleterious effects can be given a higher score.
  • the cumulative effect of its SNPs can be calculated, resulting in a “Polygenic risk factor” (PRF).
  • PRF Polygenic risk factor
  • Exemplary PRFs for a given SNP category can be multiplied in the dosage formula to determine the dosage for the respective SNP category.
  • Table 4 includes a summary of the genotype values and the PRFs for the respective exemplary skin-related SNPs.
  • a PRF is an estimate of an individual’s genetic risk for some trait, obtained by aggregating and quantifying the effect of many common variants in the genome.
  • the PRF provides a measure of the risk of a disease or disease-related trait for an individual due to the individual’s genes across the human genome.
  • a PRF can be an average of the polymorphisms in a SNP category. For example, when 13 polymorphisms are used in melanin synthesis in Table 4, the PRF is the average of the 13 polymorphisms.
  • the PRF can be used to provide ‘Topicals Suggestions’ based on the risk associated with the conditions caused by skin-related SNPs (see Table 5). In some embodiments, the PRF can also be used to provide ‘Supplement Suggestions’ based on the risk associated with the conditions caused by skin-related SNPs (see Table 6).
  • the skin questionnaire may determine the supporting topicals and/or supplements required for certain conditions, and the PRF may determine the supporting topicals and/or supplements required for conditions brought about by skin-related SNPs. In one embodiment, the PRF further determines the amount of recommended supporting topicals and/or supplements required for conditions brought about by skin-related SNPs (tables 4 and 5).
  • topical and/or supplement blend can be modified according to the individual’s genetics.
  • the methods further comprise determining a polygenic risk factor according to the genetic statuses of the one or more locations of the plurality of genes.
  • determining the personalized dosage further comprises determining the personalized dosage of the skin topicals and/or supplements for the subject according to the polygenic risk score.
  • determining a polygenic risk factor according to the genetic statuses of the one or more locations of the plurality of genes comprises: for each of the one or more locations of a gene, assigning a genotype value according to presence or absence of a polymorphism at the location of the gene; and combining the genotype values across the locations of the plurality of genes.
  • the one or more polymorphisms are selected from Table 4.
  • a risk factor can comprise testing for one, two, three, four, five, or more of the polymorphisms provided in Table 4.
  • the skin product can be customized to meet an individual’s skin needs based on his/her genetic skin profile.
  • genetic testing can aid in determining the best form of topicals and supplements based on polymorphisms affecting biological pathways that impact skin health.
  • Table 5 lists topical suggestions for various SNP categories including melanin synthesis, moisturization, skin inflammation, melanocyte damage, collagen degradation, elastin synthesis, antioxidant status, vitamin A deficiency, vitamin B6 deficiency, vitamin B12 deficiency, vitamin C deficiency, vitamin D deficiency, folate deficiency, and omega fatty acid deficiency.
  • the topical suggestions in Table 5 are determined based on the PRFs.
  • several vitamin A polymorphisms in the BCMO1 gene may result in low levels of vitamin A in the body thus giving rise to a vitamin A deficiency. This may cause wrinkles and accelerate aging.
  • topicals such as retinol, vitamin E, resveratrol, baicalin, B vitamins, and vitamin C are recommended to be applied on a particular area of the skin, to improve the skin health issues caused by vitamin A deficiency.
  • Supplements can help with improving various factors affecting the skin.
  • the results from the genetic analysis help ascertain the fundamentals that are affecting a person’s skin.
  • appropriate supplements can be suggested to improve the root cause of the underlying skin conditions.
  • the phenotypic outcomes of the tested SNPs along with the appropriate set of supplements that help improve the skin conditions are shown in Table 6. This table lists supplement suggestions for various SNP categories including melanin synthesis, moisturization, skin inflammation, melanocyte damage, collagen degradation, elastin synthesis, antioxidant, and nutritional needs.
  • supplements may also be administrated to the individual in addition to the application of topical medications.
  • Subjects may be supplemented with the active form of vitamin A, epigallocatechin gallate, collagen, nicotinamide riboside, nicotinamide mononucleotide, coenzyme Q10, vitamin C, or curcumin, which is readily used by the body, to optimize vitamin A levels.
  • the general supplements are selected from Table 6. The supplements are determined based on the PRFs calculated in Table 4. While the concentration or the degree to which each supplement is added to the customized skin product may change when there is a change of PRFs derived from the genetic testing, the concentration or degree of the supplement can only change up to advisable values.
  • obtaining or having obtained genetic statuses of one or more genomic locations is based on determining methylation patterns of certain genes that are believed to affect the human skin and aging from different aspects.
  • Methylation is a biochemical process of adding a methyl group (CPF) to a molecule, which can influence gene expression, protein function, and cellular behavior.
  • CPF methyl group
  • Methylation plays a role in aging, skin cell regeneration, and even in the skin’s ability to repair damage from environmental stressors, such as UV rays, pollution, and inflammation.
  • Methylation impacts DNA and gene regulation, including those genes involved in the aging process. When people gets older, methylation patterns in skin cells can change, potentially leading to less effective skin repair and renewal. In some cases, “aberrant” methylation can switch off genes that promote youthful skin structure (e.g., collagen production), leading to wrinkles, sagging, and dullness.
  • DNA damage in skin cells is caused by factors like UV radiation and oxidative stress. Proper methylation helps regulate DNA repair processes. Further, methylation is important in detoxification pathways. In the liver, methylation helps detoxify harmful compounds, but it’s also relevant for skin cells, which are constantly exposed to toxins from the environment. Even more, epigenetics described above is also highly connected to methylation. For these reasons, personalized skincare products might be able to target individual epigenetic and/or methylation profiles, tailoring treatments that specifically address how a person’s skin ages or reacts to the environment.
  • Methods for generating epigenetics information can involve obtaining a sample from a subject, processing the sample to obtain nucleic acids (e.g., cell free DNA), and performing a methylation assay (e.g., assay 120).
  • a methylation assay can, in various embodiments, include a performing a conversion (e.g., a bisulfite conversion) of nucleic acids, amplifying certain target regions of the converted nucleic acids, and sequencing nucleic acids to generate the epigenetics information. Further details for performing methylation assays (e.g., nucleic acid conversion, amplification, sequencing) to generate epigenetics information are described in W02020069350, which is incorporated by reference in its entirety.
  • performing the methylation assay results in generation of epigenetics information.
  • Epigenetics information includes methylation statuses for a plurality of genomic sites.
  • the plurality of genomic sites may be one or more CpG sites whose differential methylation are informative for the skin condition of a subject.
  • a CpG site is portion of a genome that has cytosine and guanine separated by only one phosphate group and is often denoted as “5' — C — phosphate — G — 3'”, or “CpG” for short.
  • processing nucleic acids to capture methylation modifications includes performing any of nucleic acid amplification, polymerase chain reaction (PCR), methylation specific PCR, bisulfite pyrosequencing, single-strand conformation polymorphism (SSCP) analysis, methylation-sensitive single-strand conformation analysis restriction analysis, high resolution melting analysis, methylation-sensitive single-nucleotide primer extension, restriction analysis, microarray technology, next generation methylation sequencing, nanopore sequencing, and combinations thereof.
  • PCR polymerase chain reaction
  • SSCP single-strand conformation polymorphism
  • the enzymatic conversion comprises subjecting the nucleic acid to TET2, which oxidizes methylated cytosines, thereby protecting them, and subsequent exposure to APOBEC, which converts unprotected (unmethylated) cytosines to uracils.
  • the method disclosed herein identify methylation patterns for certain genes that are believed to affect human skin from different aspects.
  • the exemplary genes and the associated factors for skincare are listed in Table 7, which includes seven categorized genes, their relevant function to skin and their respective methylation-related effects.
  • gene ELN relates to elastin production and is categorized into the ‘skin firming and elasticity” category. Methylation of gene ELN reduces elastin production, causing skin to lose firmness and elasticity. Accordingly, by testing the methylation of this gene, its allows to find ingredients or nutrients that support methylation pathways.
  • the testing of methylation patterns of specific genes includes analyzing DNA to determine the extent and pattern of methylation at specific sites within the genome. This includes analyzing DNA from blood, saliva, buccal swabs, skin biopsy, urine samples, and the like using bisulfite conversion, sequencing, or methylationspecific PCR, pyrosequencing, among other possible methods.
  • a methylation score is further generated based on the tested methylation patterns of certain genes.
  • the biological age also referred to ‘methylation age’
  • the methylation age is calculated based on the Equation (1):
  • Methylation Age in each category ⁇ (Methylation Level of Gene x Weight) (1)
  • the category refers to one of the seven categories shown in Table 7, and weight for each gene can be also found in Table 7.
  • an epigenetics age is further generated based on the determined methylation age and a determined phenotype age as will be described later.
  • the epigenetics age is calculated based on the following Equation (2):
  • determining the customized skin regimen for a subject using both the levels of the plurality of skin biomarkers and the genetic statuses of one or more genomic locations of a plurality of genes includes determining the customized skin regimen for the subject using the determined methylation score, among other possible scores or parameters.
  • the customized skin regimen for the subject is determined based on the determined methylation age in each of the aforementioned seven categories shown in Table 7.
  • the customized skin regimen for the subject is determined based on the determined epigenetics age in each category.
  • AGEs advanced glycation end products
  • AGEs carboxyethyllysine (CEL), [N-(carboxymethyl)lysine] (CML), glucosepane, and pentosidine have been associated with skin aging. Their binding with skin collagen increases with increasing age.
  • Skin glycation is defined as the aging reaction of naturally occurring sugars and dermal proteins. In the skin, collagen is more likely to be glycated due to a slow turnover rate.
  • AGEs act directly on skin cells, by decreasing cell functions via the activation of inflammatory signaling pathways and oxidative stress through cell surface receptors, resulting in skin problems such as dullness, pigmentation, and wrinkles. Moreover, AGEs crosslink with collagen and elastin in the extracellular matrix and promote the loss of skin elasticity.
  • UV radiation also leads to excessive AGEs formation.
  • the UV radiation combined with AGEs action then leads to accelerated skin aging.
  • the methods disclosed herein test the urine and blood of an individual for the presence of important AGEs associated with skin glycation.
  • the most important AGEs to be tested are listed in Table 8, which include carboxymethyl lysine (CML), carboxyethyl lysine (CEL), glucosepane, and pentosidine, as applicable.
  • CML carboxymethyl lysine
  • CEL carboxyethyl lysine
  • glucosepane glucosepane
  • pentosidine as applicable.
  • This test can help estimate the degree of skin glycation. For example, if pentosidine in skin collagen is presented in an individual’s urine sample, this individual’s food and routine will be adjusted to slow down skin aging and related disorders (e.g., wrinkles, age spots, etc).
  • the test of skin glycation can be used to generate appropriate dietary, supplement
  • the methods further comprise obtaining or having obtained levels of one or more advanced glycation end products from urine or blood of a subject.
  • the advanced glycation end products comprise one or more of carboxymethyl lysine (CEL), carboxymethyl lysine (CML), glucosepane, or pentosidine.
  • CEL carboxymethyl lysine
  • CML carboxymethyl lysine
  • glucosepane glucosepane
  • pentosidine pentosidine
  • the skin is the largest organ with an abundance of folds, invaginations, and specialized niches that host a wide range of microorganisms.
  • the skin microflora comprises bacteria, fungi, and viruses.
  • Commensal microorganisms occupy a wide range of skin niches and protect the skin against invasion by more pathogenic or harmful organisms, which contribute to tissue integrity and immune homeostasis.
  • the bacterial genera Streptococcus, Corynebacterium, Propionibacterium Brevibacterium, and Micrococcus are the major skin colonizers. Malassezia spp., are the fungal species that are especially prevalent in sebaceous areas.
  • the skin commensal virome comprises eukaryotic viruses and bacteriophages, where bacteriophages are predominant.
  • P. acnes is associated with acne.
  • Acne is an inflammatory disorder of the pilosebaceous unit (hair follicle, hair shaft, and sebaceous gland).
  • An increase in P. acnes may cause the elevated secretion of lipases, proteases, and hyaluronidases that injure the tissue lining of the pilosebaceous unit, eventually resulting in acne.
  • Atopic dermatitis (AD) which is commonly known as eczema or contact dermatitis, is characterized by inflammation, redness, and irritation of the skin. AD is associated with .S'.
  • Table 9 provides an exemplary illustration of skin microbiome assessment. This assessment includes evaluation of the level of skin microbiota on particular skin surfaces of an individual leading to various skin conditions or ailments.
  • the skin conditions include acne vulgaris, rosacea, atopic dermatitis, seborrheic dermatitis, pigmented skin, increased sebum, wrinkles, skin aging, etc.
  • the method comprises obtaining or having obtained abundance of one or more microorganisms from skin niches of a subject.
  • the microorganisms comprise one or more of Propionibacterium acnes, Propionibacterium avidum, or Propionibacterium granulosum, optionally from forehead of the subject.
  • the microorganisms comprise Propionibacterium acnes, optionally from cheek of the subject.
  • the microorganisms comprise one or more of Staphylococcus epidermidis, Corynebacterium spp, or Propionibacterium acnes, optionally from nasolabial fold of the subject.
  • the microorganisms comprise Propionibacterium acnes, optionally from chin of the subject.
  • the microorganisms comprise Propionibacterium acnes, optionally from chin of the subject.
  • the microorganisms comprise one or more of Corynebacterium kroppenstedtiin or Staphylococcus epidermidis, optionally from cheek of the subject.
  • the microorganisms comprise Corynebacterium kroppenstedtiin, optionally from nasolabial fold of the subject. [00211] In some embodiments, the microorganisms comprise Staphylococcus epidermidis, optionally from eyelid of the subject.
  • the microorganisms comprise Staphylococcus epidermidis, optionally from cheek of the subject.
  • the microorganisms comprise Corynebacterium species, optionally from chin of the subject.
  • the microorganisms comprise Malassezia spp, optionally from cheek of the subject.
  • the microorganisms comprise Acinetobacter, optionally from cheek of the subject.
  • the microorganisms comprise Corynebacterium, optionally from cheek of the subject.
  • the microorganisms comprise one or more of Corynebacterium amycolatum, Proteobacteria, Firmicutes, Bacteroidetes, or Propionibacterium, optionally from forehead of the subject.
  • the microorganisms comprise Propionibacterium, optionally from cheek of the subject.
  • the microorganisms comprise one or more of Corynebacterium, Lactobacillus, or Cutibacterium, optionally from face of the subject.
  • Demographics can be a component used in providing a customized skin regimen. Changes in demographics such as age and gender can alter a subject’s skin conditions. Thus, demographics can be factored into the evaluation of the skin regimen, for determining topicals applied to a particular area of the skin, for determining supplementing nutrients, and for monitoring the progress of the implemented topicals and dietary/supplement interventions in a subject.
  • An individual’s age is a critical factor affecting skin health. Advancing age is associated with structural and functional changes in extracellular matrix components such as collagens, elastin, and proteoglycans that are required to provide tensile strength, elasticity, and hydration to the skin. The accompanied phenotypic changes are loss of plump and smooth skin, visible veins and bone structure, and increased scarring.
  • Gender is another key factor influencing skin health.
  • An individual’s skin is influenced by sex-related differences in anatomy, physiology, epidemiology, and the manifestations of several diseases. Skin parameters such as hydration, transepidermal water loss, sebum, microcirculation, pigmentation, and thickness are generally higher in men while skin pH is higher in women. These differences may be related to hormones. For example, sebum content can be elevated in men because sebum is highly influenced by sex hormones.
  • These sex-related differences may also play a role in disease susceptibility with infectious diseases being presented more in men but psychosomatic problems, pigmentary disorders, certain autoimmune and allergic diseases being more prevalent among women. However, the mechanisms that underlie sex-related differences in skin diseases are yet to be elucidated.
  • the methods disclosed herein further comprise obtaining or having obtained demographics of the subject, and determining the customized skin regimen for the subject based on the demographics of the subject.
  • the demographics comprise one or more of an age or gender of the subject.
  • the phenotypic appearance of the skin is an obvious indicator of skin health, which is another factor considered and addressed in the methods disclosed herein.
  • a visual evaluation may provide the status of the skin and also represent tangible improvements expected by individuals. Such visual evaluations help with addressing visible skin concerns, and have widely been used in diagnosis as well as experimental dermatology. However, a crucial, visual assessment can be subjective and differs from one assessor to the other. To overcome this drawback, a digital system is proposed herein in this disclosure to analyze the phenotypic features of the skin.
  • the system disclosed herein may involve capturing images of an individual’s skin.
  • the captured image can be of the individual’s skin from any anatomical location of the individual.
  • the captured image is of the individual’s face. These images may be taken at different angles. For example, the images can be taken from the front of the face and from two sides of the face.
  • the inbuilt system may grade the severity of each phenotypic parameter. A consensus on the degree of severity may be determined with the help of experts in the field.
  • the system disclosed herein may provide a questionnaire to an individual in the phenotypic appearance assessment, as described later in the ‘Skin Questionnaire’ section. Based on the feedback from the questionnaire, the inbuilt system may grade the severity of each phenotypic parameter.
  • Table 10 illustrates an exemplary grading system for grading the severity of phenotypic parameters from seven different categories, namely, an anti-aging and wrinkle reduction category, a lymphatic drainage category, a skin firming and elasticity category, a brightening and pigmentation category, a UV/oxidative damage/DNA/cell damage category, an anti-inflammatory and soothing category, and a hydration and skin barrier repair category.
  • the inbuilt grading system includes a picture-based grading algorithm and a questionnaire-based algorithm.
  • the picture-based grading algorithm provides a scale of 1-10 (where 1 is the best and 10 is the worst) for each of the seven categories based on the image evaluation from different aspects.
  • the questionnaire-based algorithm provides a score for each category based on the information collected form the questionnaire. As can be seen in Table 10, instead of the scale of 1-10 for all seven categories, the questionnaire-based algorithm provides different scales for different categories, for example, a scale of 0-3 for ‘lymphatic drainage’, a scale of 0-6 for ‘anti-aging and wrinkle reduction’, and a scale of 0-8 for ‘hydration and skin barrier repair”.
  • the inbuilt system disclosed herein further generates a phenotype age for each of the seven categories. For example, based on the obtained points from the picture -based grading and questionnaire-based grading (e.g., the sum of the two grading outcomes), a phenotype age is further determined for the subject under the assessment for each of the seven categories.
  • Table 11 illustrates an exemplary grading principle for determining the phenotype age of a subject under the assessment. In the exemplary grading illustrated in the table, the phenotype age of the subject under the assessment can be determined to have a phenotype age of 30-70.
  • the phenotype ages can have other different ranges, which is not limited in the disclosure.
  • the determined phenotype ages for different categories may be different, which can provide information which category(ies) should be focused when determining the customized topical, supplements and lifestyle suggestions. For example, if ‘brightening and pigmentation’ has a determined phenotype age of 40 while all other six categories have a determined phenotype of 30, the determined customized topical, supplements and lifestyle suggestions are more focused on the skin brightening and pigmentation.
  • the disclosed methods based on the obtained phenotype age for each of the seven categories, the disclosed methods further determine the epigenetics age, as described earlier.
  • Table 12 shows exemplary suggestions for topical, supplements, and lifestyles, which are generated based on phenotypic assessment over a set of phenotypic parameters such as wrinkles, periorbital-around eyes, etc.
  • the suggestions may be determined based on the graded severity of each phenotypic parameter. For example, when determining topical supplementation, a higher severity may cause the system to provide a higher concentration of topical ingredients. It should be noted, however, that an increase in topical ingredients will only take place up to one or more safe, advisable limits.
  • the methods disclosed herein further comprise obtaining or having obtained an image of a face from a subject, grading severities of one or more phenotypic parameters for the face of the subject based on the image, and determining the customized skin regimen for the subject based on the severity of the one or more phenotypic parameters.
  • the grading is point-based and have a scale of 1-10 where 1 represents the best and 10 represents the worst.
  • the methods disclosed herein further comprising obtaining or having obtaining feedback for a questionnaire sent to a subject, grading severities of one or more phenotypic parameters for the subject based on the feedback of the questionnaire, and determining the customized skin regimen for the subject based on the severity of the one or more phenotypic parameters.
  • the methods disclosed herein further comprising obtaining or having obtaining a phenotype score for one or more categories for a subject and determining the customized skin regimen for the subject based on the phenotype score of the one or more categories.
  • the aforementioned phenotype age may be used as the phenotype score for each of the seven categories described above.
  • the phenotypic parameters comprise one or more of wrinkles, periorbital-around eyes (i.e., puffy eyes), nasolabial folds (i.e., laugh lines), worry lines, uneven skin tone or pigmentation, or age spots (i.e., liver spots).
  • the phenotypic parameters are categorized into seven different categories as shown in Table 10 and Table 11. Skin Questionnaire
  • a skin questionnaire is employed to query an individual’s concerns and needs.
  • the questionnaire addresses various factors such as skin goals, type of skin, sun exposure, and skin proneness to external factors, sensitivity to skin products, etc. It also takes into account whether individuals are undergoing or have undergone skin treatments or cosmetic procedures because certain treatments and cosmetic procedures may alter the skin’s structure and composition, which can in turn affect the skin’s ability to absorb and react to skincare products.
  • the skin questionnaire can assist with the selection of suitable skin topical and/or supplement forms to ameliorate certain symptoms and overall improve the subject’s skin health.
  • the skin questionnaire may comprise the following questions: if any of the following goals was a primary goal for the subject’s skin: UV protection, anti- wrinkling, antipigmentation, moisturization, radiant complexion; if the subject’s skin was dry; if dry, was the skin mild dry, very dry, or extremely dry; if the subject had specific oily areas on his/her face while the rest of the areas may experience a certain level of dryness; if the subject’s skin was prone to acne; the amount of time (1 hour, 1-2 hours, or > 2 hours) the subject got sun exposure every day; if the subject has ever or is currently receiving skin treatments; if receiving or has received skin treatments, list the treatments; if the subject has stinging or burning after applying any/most skin products; if the subject has excessive scratching, excessive peeling, pus and oozing; if the subject has excessive scratching,
  • the questionnaire can help determine the presence of complications or symptoms associated with altered topical and/or supplement levels, susceptibility to side effects that may be associated with topicals and/or supplements, presence of comorbidities and their symptoms, or ongoing medication usage by the subject.
  • the questionnaire can assess these aspects using direct questions which could be answered with either a ‘yes’ or a ‘no.’
  • the questionnaire can also receive the subject’s selections for certain other answers to the questions.
  • a grading system can be further applied to generate a questionnaire score for the skin questionnaire.
  • Points can be assigned to each selected answer, as illustrated in Table 13. For example, if the question is ‘How often do you notice fine lines or wrinkles on your skin,’ the answer can be ‘Never,’ ‘Occasionally,’ ‘Frequently,’ and ‘Always.’ The four different answers have respective points of 1, 2, 3, and 4. For other questions included in the questionnaire, each answer also has a corresponding point assigned in advance. Based on the answers feedback from the questionnaire, one or more questionnaire scores can be then generated.
  • a questionnaire score may be obtained for each categories (e.g., sum of the points corresponding to the selected answers to all questions included in the category).
  • an overall questionnaire score can be generated based on the selected answers to all questions included in the questionnaire.
  • Responses to the skin questionnaire or the determined questionnaire score(s) can determine appropriate suggestions for topicals, supplements, and lifestyle of the subject.
  • Table 14 provides exemplary responses for the skin questionnaire and the customized topical, supplement, and lifestyle recommendations.
  • Hyaluronic acid can act as a barrier to prevent water loss through evaporation, reduces trans epidermal water loss (TEWL), and improves the skin’s ability to retain moisture.
  • TEWL trans epidermal water loss
  • glycerin can be applied to create a thin, occlusive layer to help seal in moisture and prevent water loss through evaporation, shea butter resembles the natural lipids found in the skin to enhance moisture retention, while jojoba oil resembles the natural sebum to form a non-greasy protective barrier on the skin’s surface to prevent trans epidermal water.
  • the individual is also recommended to intake supplements such as hyaluronan, ceramides, and collagen to incorporate with the above-mentioned skin barriers to strengthen the skin and improve moisture retention.
  • supplements such as hyaluronan, ceramides, and collagen
  • the individual is taking long hot baths, he/she may want to take quicker shower with colder water. If the individual is not using a humidifier, he/she may try to use it.
  • This kind of lifestyle suggestions as well as the use of topicals and/or supplements can be personalized and used by specific persons to meet their specific skin needs.
  • the combination of skin biomarker testing, demographic considerations, and the skin questionnaire can enable improving the individual’s overall skin health.
  • the methods disclosed herein further comprise obtaining or having obtained one or more responses to a skin questionnaire from the subject and determining the customized skin regimen for the subject based on the one or more responses from the subject.
  • the customized skin regimen includes one or more suggestions for topicals, supplements, or lifestyles determined based on the one or more responses, and the one or more suggestions can be selected from Table 14.
  • the skin questionnaire comprises one or more questions related to skin goals, type of skin, sun exposure, or skin proneness to external factors.
  • the method disclosed herein offers testing for various skin parameters using biomarkers (serum, sebum, urine, any biospecimen) along with many genetic predispositions that may affect an individual’s skin health. These results are used to create customized skin products that would improve the individual’s skin health based on his/her skin profile. However, the skin is also affected by other factors such as metabolism and nutrition. Therefore the methods disclosed herein also offer tests to assess metabolism and nutrient levels to help understand the other fundamental causes affecting the skin.
  • biomarkers serum, sebum, urine, any biospecimen
  • Hormones are crucial for skin health as they play an important role in the development and physiological function of human skin tissues.
  • the skin has been the target for various hormones in the body.
  • sebaceous glands are the targets for androgen steroids that are secreted by the gonads and the adrenal cortex.
  • Some hormones are even produced in the skin.
  • the circulating androgens dehydroepiandrosterone (DHEA) and androstenedione are converted to testosterone or 5a-dihydrotestosterone (5 a- DHT) in the skin. This makes the skin responsible for considerable amounts of the circulating 5a-DHT levels.
  • DHEA dehydroepiandrosterone
  • 5 a- DHT 5a-dihydrotestosterone
  • the skin expresses receptors for peptide hormones while the receptors for steroid and thyroid hormones are found in the cytoplasm or nuclear compartments of skin cells. From the modem dermato-endocrinologic point of view, the skin is not only the recipient but also the orchestrator of various endocrine signals.
  • the methods disclosed herein further comprise a ‘HormonePro’ test which tests for various urine and blood hormones along with genetic assessment for SNPs affecting hormone functions. HormonePro tests could provide insights into a subject’s hormone profile that is correlated to the status of the subject’s skin. Based on HormonePro test results, a customized skin regimen (including dietary and supplement suggestions) can be generated to improve hormone functions.
  • a ‘HormonePro’ test which tests for various urine and blood hormones along with genetic assessment for SNPs affecting hormone functions. HormonePro tests could provide insights into a subject’s hormone profile that is correlated to the status of the subject’s skin. Based on HormonePro test results, a customized skin regimen (including dietary and supplement suggestions) can be generated to improve hormone functions.
  • Table 15 provides an exemplary list of biomarkers that can be tested in the ‘HormonePro’ test along with the respective directionality, exemplary supplements, and dosages for males that can improve the indicated biomarker levels and the associated skin conditions.
  • the methods disclosed herein comprise obtaining or having obtained the levels of one or more hormones (i.e., hormone biomarkers).
  • Obtaining the levels of hormones comprises determining one or more combinations of levels of the one or more hormones.
  • the hormone markers are obtained from urine samples of a subject.
  • the subject is a male (Table 15), and the hormone markers comprise one or more of estrone (El), estradiol (E2), dehydroepiandrosterone (DHEA), testosterone, epi-testosterone (Epi-T), androstenedione (AD), androsterone, etiocholanolone, 5-alpha- dihydrotestosterone (5a-DHT), dehydroepiandrosterone sulfate (DHEA-S), progesterone (P), cortisol, cortisone, b-tetrahydrocortisol (b-THF), a-Tetrahydrocortisol (a- THF), b-Tetrahydrocortisone (b-THE), deoxycorticosterone, corticosterone, melatonin, or 8- hydroxy-2' -deoxy guanosine (8-OHdG).
  • estrone El
  • estradiol E2
  • determining one or more combinations of levels of the one or more hormones comprises determining one or more of Estriol (E3)/(E1+E2), 2-OH (El + E2)/16a-OH El, 2-MeO E1/2-OH El, 4-MeO E1/4-OH El, 4-MeO E2/4-OH E2, testosterone (T)/Epi-T, b-pregnanediol/E2, cortisol/cortisone, or metabolized cortisol (THF+THE), or Prostaglandin (Pg)/E2.
  • Table 15 provides an exemplary list of biomarkers that can be tested in the ‘HormonePro’ test along with the respective directionality, exemplary supplements, but includes dosages for females.
  • the methods disclosed herein further comprise obtaining or having obtained the levels of one or more hormones (hormone biomarkers).
  • Obtaining the levels of hormones comprises determining one or more combinations of levels of the one or more hormones.
  • the hormone markers are obtained from urine samples of a subject.
  • the subject is a female (table 11)
  • the hormones comprise one or more of estrone (El), estradiol (E2), Estriol (E3), total estrogen, 2-OH estradiol, 2-OH estrone, 4-OH estradiol, 4-OH estrone, dehydroepiandrosterone (DHEA), androstenedione, androsterone, etiocholanolone, 5-alpha- dihydrotestosterone (5a-DHT), 5a, 3a- Androstanediol, 5P-Androstanediol, dehydroepiandrosterone sulfate (DHEA-S), progesterone, allopregnanolone, allopregnanediol, 3a-dihydroprogesterone, 20a- dihydroprogesterone, b-pregnanediol, a-pregnanediol, cortisol,
  • estrone est
  • determining one or more combinations of levels of the one or more hormones further comprises determining one or more of E3/(E1+E2), 2-OH (El + E2)/16a-OH El, 2-MeO E1/2-OH El, 4-MeO E1/4-OH El, 4-MeO E2/4-OH E2, T/Epi-T, b-pregnanediol/E2, cortisol/cortisone, or metabolized cortisol (THF+THE), or Prostaglandin (Pg)/E2.
  • the hormone biomarkers include one or more urinary biomarkers selected from Table 15 or Table 16 (described below).
  • the supplement is administered to the subject to improve hormone levels or functions.
  • the dosage for males is selected from Table 15.
  • the dosage for females is selected from Table 16.
  • the skin protects the body against environmental stressors such as solar radiation, industrial pollution, and carbon emissions.
  • environmental stressors such as solar radiation, industrial pollution, and carbon emissions.
  • this protection makes it highly susceptible to premature accelerated aging due to the cumulative damage caused by these external factors.
  • One of the hallmarks of skin aging is alterations in metabolic processes (intrinsic factor), particularly mitochondrial dysfunction, which may lead to skin aging phenotypes such as wrinkle formation, uneven pigmentation, and decreased wound healing. Additionally, alterations in metabolic processes may also result in the loss of barrier function that increases susceptibility to infection and affects wound healing.
  • Nutrition is an important extrinsic factor that affects skin aging. It has been known that increased intake of carbohydrates is associated with accelerated skin aging, and may damage the skin’s vital components through nonenzymatic glycation, the covalent attachment of sugar to a protein, and subsequent production of advanced glycation end products (AGEs). Glucose and fructose link the amino acids present in the collagen and elastin that support the dermis. This leads to the production of AGEs that accelerate skin aging.
  • the intercellular lipids, such as triglycerides, cholesterol, free fatty acids, etc., in the skin’s epidermis are important for the maintenance of skin moisture and elasticity. They provide proper epidermal barrier function.
  • keratins keratins
  • collagen keratins
  • elastin elastins
  • amino acids are important for various integral skin functions such as wound healing, maintaining the acid-base balance and water retention in cellular layers (stratum corneum), protecting against sun damage, and maintaining the skin microbiome. Poor amino acid metabolism can result in sagging and wrinkled skin.
  • the methods disclosed herein further comprise a ‘MetabolicPro’ test which assesses serological and urological metabolism markers.
  • MetabolicPro test can also assess SNPs that affect cellular, carbohydrate, lipid, and amino acid metabolism. MetabolicPro test helps draw correlations between the fundamental metabolic factors that could be affecting the skin. Based on the MetabolicPro test results, a customized skin regimen (including dietary and supplement suggestions) can be generated to improve various metabolic functions.
  • the results from the ‘MetabolicPro’ test can determine an individual’s metabolism status and help determine the appropriate supplementation to be provided to the individual.
  • Table 17 provides an exemplary list of biomarkers that can be tested in the ‘MetabolicPro’ test along with exemplary supplements, and dosages for males and females that can improve the biomarker levels and their associated condition.
  • the methods disclosed herein further comprise obtaining or having obtained the levels of one or more metabolism markers from serum or urine of the subject.
  • the metabolism markers comprise one or more serum metabolism biomarkers.
  • the serum metabolism biomarkers comprise one or more of lipid metabolism biomarkers, carbohydrate metabolism biomarkers, or cellular biomarkers.
  • the lipid metabolism biomarkers comprise one or more of vaccenic acid, adiponectin, acylhexosylceramide (AHC), diacylglycerol (DAG), dimethylphosphatidy lethanolamine (DMPE), or plasminogen activator inhibitor- 1 (PAI-1.
  • the carbohydrate metabolism biomarkers comprise one or more of adiponectin, gastric-inhibitor-peptide (GIP), or leptin.
  • the cellular biomarkers comprise nicotinamide adenine dinucleotide (NAD).
  • the metabolism markers comprise one or more urine metabolism biomarkers.
  • the urine metabolism biomarkers comprise one or more of lipid metabolism biomarkers or carbohydrate metabolism biomarkers.
  • the lipid metabolism biomarkers comprise one or more of adipate, suberate, or ethyl malonate.
  • the carbohydrate metabolism biomarkers comprise one or more of pyruvate, L-lactate, or P-hydroxybutyrate.
  • the supplement is administered to improve metabolic functions.
  • the metabolism marker is one or more biomarkers selected from Table 17.
  • the supplement is one or more supplements selected from Table 17.
  • the dosage for men or the dosage for women is selected from Table 17.
  • Nutrients play a major role in skin health and disease.
  • vitamin A prevents UV skin damage by regulating the proliferation of epidermal keratinocytes and dermal fibroblasts.
  • Vitamin C protects against oxidative stress by suppressing UV irradiation-triggered production of free radicals. Vitamin C also promotes cutaneous wound healing and increases epidermal moisture content, thereby improving skin hydration.
  • Vitamin D enhances innate immunity and regulates inflammation, angiogenesis, and wound healing.
  • Vitamin E reduces lipid peroxidation, modulates photoaging, and exhibits antiinflammatory which is beneficial for skin health.
  • the mineral zinc protects the skin owing to its antibacterial properties and also reduces photodamage. Copper acts as an antioxidant to stimulate the maturation of collagen and regulate collagen synthesis.
  • Selenium the major antioxidant of the human body, protects the skin against UV irradiation-induced oxidative stress.
  • the methods disclosed herein further comprise a ‘NutriLite’ test and a more comprehensive ‘NutriPro’ test for assessing nutrient deficiencies.
  • Table 18 provides an exemplary list of vitamins and minerals in serum that can be examined in ‘NutriLite’ test.
  • the method provided herein further comprises obtaining or having obtained the levels of one or more nutrients from the subject.
  • the nutrients comprise one or more vitamins or minerals (table 13).
  • the vitamins or minerals comprise one or more of Folate (L-5-methyltetrahydrofolate), magnesium, iron, vitamin A (retinol), vitamin D3
  • the comprehensive nutrient panel ‘NutriPro’ tests the levels of various nutrients in the body along with genetic testing for predispositions due to nutrient deficiencies. Table 19 provides an exemplary list of nutrients that can be examined in NutriPro test.
  • the nutrients tested in NutriPro test comprise one or more vitamins and minerals, amino acids, or fatty acids (table 15).
  • the levels of these nutrients can be measured from serum, white blood cells (WBCs), or red blood cells (RBCs).
  • the vitamins and minerals comprise vitamin A (retinol), vitamin A (beta-carotene), vitamin Bl (thiamine diphosphate), vitamin B2 (riboflavin 5- phosphate), vitamin B3 (nicotinic acid), vitamin B5 (pantothenic acid), vitamin B6, pyridoxal 5-phosphate, vitamin B7 (biotin), vitamin B12 (cyanocobalamin), vitamin C (L-ascorbic acid), vitamin D (25-OH), vitamin D3 (cholecalciferol), vitamin D (1-25 dihydroxy), vitamin E (alpha-tocopherol), vitamin KI (phylloquinone), vitamin K2 (menaquinone-MK-7), folate (L- 5 -methyltetrahydrofolate), coenzyme Q10 (ubiquinone + ubiquinol), selenium, sodium, potassium, calcium, zinc, manganese, iron, magnesium, copper, chromium, myoinositol, iodine
  • the amino acids comprise one or more of glutathione (oxidized), methylmalonic acid (MMA), choline, L-cysteine, L-asparagine, L-glutamine, L- serine, L-arginine, L-citrulline, L-isoleucine, L-valine, L-leucine, free carnitine, or phenylalanine.
  • the fatty acids comprise one or more of docosahexaenoic acid (DHA), Eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), arachidonic acid (AA), or linoleic acid (LA).
  • DHA docosahexaenoic acid
  • EPA Eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • AA arachidonic acid
  • LA linoleic acid
  • the method provided herein further comprises determining one or more combinations of levels of one or more of the vitamins and minerals.
  • determining one or more combinations of levels of one or more of the vitamins and minerals further comprises obtaining a ratio of copper/zinc.
  • the method provided herein further comprises determining one or more combinations of levels of one or more of the fatty acids.
  • determining one or more combinations of levels of one or more of the fatty acids further comprises obtaining omega-3 total, omega-6 total, omega-3 index, or a ratio of AA/EPA.
  • the nutrient is one or more nutrients selected from Table 18 and Table 19.
  • the skin and the gut are highly analogous to each other in purpose and functionality. For example, they are highly innervated and vascularized, and they both are crucial for immune and neuroendocrine function.
  • the ‘gut-skin’ axis is an outcome of this resemblance. This could be the reason why gastrointestinal (GI) disturbances are often accompanied by cutaneous manifestations.
  • GI gastrointestinal
  • the gut microbiome exerts immuno-modulating effects on the skin.
  • Short-chain fatty acids (SCFAs) produced from fiber fermentation in the gut are considered to be crucial in determining the predominance of certain skin microbiome profiles that subsequently influence cutaneous immune defense mechanisms.
  • SCFAs Short-chain fatty acids
  • the gut microbiome also appears to be involved in skin barrier function by controlling the systemic modulatory effect. As a result, alterations in the gut microflora may have profound effects on the skin.
  • Gut dysbiosis leads to increased epithelial permeability which then triggers the activation of effector T cells, disrupting their balance with immunosuppressive regulatory T cells.
  • Pro-inflammatory cytokines further increase epithelial permeability, leading to chronic systemic inflammation. Therefore, a disturbed gut microbiome manifests in impaired skin function.
  • H2S hydrogen sulfide
  • the methods disclosed herein further comprise a further ‘Gut Zoomer’ Panel to test a wide range of commensal bacteria, archaea, fungi, and viruses, along with gut metabolites that can be tested. Based on ‘Gut Zoomer’ test, gut microflora modulation can be conducted to provide therapeutic potential for skin health improvement.
  • the method provided herein further comprises obtaining or having obtained the levels of one or more commensal microorganisms from the subject.
  • the commensal microorganisms comprise one or more of commensal bacteria, archaea, fungi, or viruses.
  • the method provided herein further comprises obtaining or having obtained the levels of gut metabolites from the subject.
  • methods for determining customized skin regimens for individuals based on factors described herein can involve determining a customized skin regimen that includes particular quantities of one or more of the active element provided in any of Tables 20, 21-1, 21-2, 21-3, 21-4, 21-5, 21-6, 21-7, 21- 8, 21-9.
  • the customized skin regimen includes a set of base elements, as illustrated in Table 20. Each base element has a corresponding range, and these base elements are classified into six categories e.g., polymer/solubilizing/gelling/emulsifier agents, humectant and emolient, preservative, chelating agent, penetration enhancers, and perfume.
  • a customized skin regime one (or more than one base element if necessary) is selected from each category. The exact amount of each selected base element can be specified and/or adjusted if necessary.
  • methods for determining customized skin regimens for individuals comprises analyzing one or more factors from the individual described herein.
  • methods for determining customized skin regimens for individuals comprises analyzing one or more of (A) genetics, (B) methylation patterns, (C) demographics, (D) phenotypic assessment, and (E) skin questionnaire information.
  • methods for determining customized skin regimens involves obtaining or having obtained genetics (e.g., genetic information from genetic testing), epigenetics information (e.g., methylation statuses), and/or phenotypic data (e.g., an image).
  • methods for determining customized skin regimens involves obtaining or having obtained genetics (e.g., genetic information from genetic testing), epigenetics information (e.g., methylation statuses), phenotypic data (e.g., an image), and/or skin questionnaire information.
  • methods for determining customized skin regimens involves obtaining or having obtained genetic statuses of one or more genomic locations, methylation statuses of one or more genes involved in biological processes of the skin activity category, and an image captured of the subject’s skin.
  • Genetic information can be obtained by performing methods described herein under the “Genetic Testing” heading.
  • Epigenetics information can be obtained by performing methods described herein under the “Epigenetics” heading.
  • Phenotypic data can be obtained by performing methods described herein under the “Phenotypic Assessment” heading.
  • Skin questionnaire information can be obtained by performing methods described herein under the “Skin Questionnaire” heading.
  • methods for determining customized skin regimens involves obtaining or having obtained such information for each of one or more skin activity categories, examples of which include an anti-aging and wrinkle reduction category, a lymphatic drainage category, a skin firming and elasticity category, a brightening and pigmentation category, a UV/oxidative damage/DNA/cell damage category, an antiinflammatory and soothing category, and a hydration and skin barrier repair category.
  • methods for determining customized skin regimens involves obtaining or having obtained genetics (e.g., genetic information from genetic testing), epigenetics information (e.g., methylation statuses), and/or phenotypic data for each of one or more skin activity categories.
  • Examples of skin activity categories, as well as active elements of those skin activity categories, are described in Tables 22-1 to 22-9. As an example, assume 7 different skin activity categories. Thus, methods may involve obtaining or having obtained obtaining or having obtained genetics (e.g., genetic information from genetic testing), epigenetics information (e.g., methylation statuses), and/or phenotypic data for each of the 7 different skin activity categories.
  • genetics e.g., genetic information from genetic testing
  • epigenetics information e.g., methylation statuses
  • phenotypic data for each of the 7 different skin activity categories.
  • certain information can be used across different skin activity categories whereas other information is unique to a particular skin activity category.
  • genetic statuses of different genes can be specific for a particular skin activity category, given that the biological activity of a gene can be involved in that particular skin activity category.
  • epigenetics information for different genes can be specific for a particular skin activity category, given that the biological activity of a gene can be involved in that particular skin activity category.
  • phenotypic information such as an image
  • questionnaire information can be used across different skin activity categories.
  • methods for determining customized skin regimens involves determining one or more of a methylation score, a phenotype score, and a genetic score for the skin activity category for the subject using the one or more of genetic statuses, methylation statuses, and phenotypic information.
  • the genetic score, methylation score, and phenotype score for each skin activity category may be different.
  • a personalized customized skin regimen including specifically determined amounts of individual elements can be determined for the subject.
  • Each of the genetic statuses, methylation statuses, and the phenotypic information are described in turn.
  • the genetic information can be used to determine a genetic score that is useful for determining quantities of active elements to be included in a customized skin regime.
  • the genetic information includes genetic statuses of 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 75 or more, 100 or more, 200 or more, 300 or more, 400 or more, 500 or more, 600 or more, 700 or more, 800 or more, 900 or more, or 1000 or more genomic locations.
  • genetic statuses can be indicative of a wild type or a mutation (e.g., single nucleotide polymorphisms (SNPs), insertion, deletion, etc).
  • a genetic score can be specific for a skin activity category.
  • methods can involve determining X corresponding genetic scores.
  • the genetic statuses of one or more genomic locations can be related to a particular skin activity category.
  • a genetic score can be a quantity of genetic issues detected in an individual based on the genetic information.
  • a genetic score can be 1 genetic issue, 2 genetic issues, 3 genetic issues, 4 genetic issues, 5 genetic issues, 6 genetic issues, 7 genetic issues, 8 genetic issues, 9 genetic issues, 10 genetic issues, 11 genetic issues, 12 genetic issues, 13 genetic issues, 14 genetic issues, 15 genetic issues, 16 genetic issues, 17 genetic issues, 18 genetic issues, 19 genetic issues, 20 genetic issues, 25 genetic issues, 30 genetic issues, 35 genetic issues, 40 genetic issues, 45 genetic issues, 50 genetic issues, 55 genetic issues, 60 genetic issues, 70 genetic issues, 80 genetic issues, 90 genetic issues, 100 genetic issues, or any number of genetic issues therein.
  • the epigenetic information can be used to determine a methylation score (also referred to herein as a “methylation age”) that is useful for determining quantities of active elements to be included in a customized skin regime.
  • the epigenetic information includes methylation statuses of 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 75 or more, 100 or more, 200 or more, 300 or more, 400 or more, 500 or more, 600 or more, 700 or more, 800 or more, 900 or more, or 1000 or more genomic locations.
  • Example genomic locations e.g., genes for the various skin activity categories are shown in Table 7.
  • a methylation score can be specific for a skin activity category.
  • methods can involve determining X corresponding methylation scores.
  • epigenetic information can include methylation statuses of 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 75 or more, 100 or more, 200 or more, 300 or more, 400 or more, 500 or more, 600 or more, 700 or more, 800 or more, 900 or more, or 1000 genes involved in biological processes of the skin activity category.
  • a methylation score is determined in accordance with Equation (1):
  • Methylation Age in each category ⁇ (Methylation Level of Gene x Weight) (1)
  • the category refers to one of the seven activity categories shown in Table 7, and the weight for each gene can be also found in Table 7.
  • the phenotypic information it can be used to determine a phenotype score (also referred to herein as a “Phenotypic Age”) that is useful for determining quantities of active elements to be included in a customized skin regime.
  • the phenotypic information includes an image of the individual, such as an image of the individual’s skin.
  • the phenotypic information includes an image of the individual’s face.
  • methods include analyzing the phenotypic information to convert the phenotypic information into a quantitative score that can be used, at least in part, to determine the phenotype score.
  • analyzing the phenotypic information can involve manually analyzing the phenotypic information and assigning quantitative scores for each of the skin activity categories.
  • analyzing the phenotypic information can involve applying an automated process (e.g., a machine learning or image recognition process) to analyze the phenotypic information and assigning quantitative scores for each of the skin activity categories.
  • the quantitative score can be between a minimum of 1 and a maximum of 10. For example, a score of 1 can be indicative of an optimal condition for the skin activity category whereas a score of 10 can be indicative of a worst condition for the skin activity category.
  • An example of quantitative scores from an image for individual skin activity categories is shown in Table 10.
  • a phenotype score (also referred to herein as a “Phenotypic Age”) that is useful for determining quantities of active elements to be included in a customized skin regime.
  • methods include analyzing the skin questionnaire information to convert provided answers into a quantitative score that can be used, at least in part, to determine the phenotype score.
  • the quantitative score can be between a minimum of 1 and a maximum of 3.
  • the quantitative score can be between a minimum of 1 and a maximum of 6.
  • the quantitative score can be between a minimum of 1 and a maximum of 8.
  • An example of quantitative scores from a questionnaire for individual skin activity categories is shown in Table 10.
  • example questions of the questionnaire are shown in Table 13 along with assigned points corresponding to particular answers.
  • methods involve combining the quantitative score from the phenotypic information and the quantitative score from the questionnaire to generate the phenotype score.
  • methods can involve arithmetically combining (e.g., summing) the quantitative score from the phenotypic information and the quantitative score from the questionnaire.
  • the arithmetically combined quantitative scores are mappable to a corresponding phenotype score. For example, if the arithmetically combined quantitative score falls within a particular score range, then the score is mapped to a corresponding phenotype score for that particular score range.
  • Table 11 An example is shown in Table 11 where each points range (for a particular skin activity category) corresponds to a particular phenotype score (e.g., phenotype age as referred to in Table 11).
  • methods for determining the customized skin regimen involves determining fixed values for each of a plurality of active elements of a particular skin activity category using the corresponding scores.
  • determining the fixed values involves querying a look-up table that holds the fixed values based on a corresponding score. For example, given a genetic score for a skin activity category, methods involve accessing a list of fixed values for the active elements of the skin activity category corresponding to the genetic score. Additionally, given a methylation score, methods involve accessing a list of fixed values for the active elements of the skin activity category corresponding to the methylation score. Additionally, given a phenotype score, methods involve accessing a list of fixed values for the active elements of the skin activity category corresponding to the phenotype score.
  • fixed values for each active element in a skin activity category can range between 0 and 3%.
  • a fixed value can be any of 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, or 3.0%.
  • Table 22-1 shows the fixed values for active elements in the anti-aging and wrinkle reduction skin activity category, given a genetic score (e.g., at least 1 genetic issue), a methylation score (e.g., 51-60), and a phenotype score (e.g., 41-50).
  • a genetic score e.g., at least 1 genetic issue
  • a methylation score e.g., 51-60
  • a phenotype score e.g. 41-50.
  • Table 22-1 depicts one example of fixed values of active elements, one skilled in the art would understand that there are various other combinations of fixed values that can be used (e.g., between 1 and 3%) for the various active elements.
  • methods can involve combining certain fixed values for each active element.
  • methods involve combining fixed values across one or more of the methylation score, phenotype score, and genetic score to determine a percentage of the element to be included in the customized skin regimen.
  • methods can involve combining the fixed values across one or more, two or more, or each of the methylation score, phenotype score, and genetic score to generate an average score.
  • the average score is calculated as:
  • Average score for AE Average (MSAE + PSAE) + GSAE where MSAE refers to the methylation score for the active element AE, where PSAE refers to the phenotype score for the active element AE, and where GSAE refers to the genetic score for the active element AE.
  • the average score for an active element can represent the quantity of the active element to be included in the customized skin regimen.
  • the average score for an active element can further undergo a scaling transformation to determine a scaled score representing the quantity of the active element to be included in the customized skin regimen.
  • the scaling factor is between 0 and 1.
  • the scaling factor is a value of 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, or 0.95.
  • the scaling factor is a value of 0.75. Examples of average scores and scaled scores for each active element across various skin activity categories are shown in Tables 22- 1 to 22-9.
  • FIG. 3 a flowchart of an exemplary method for determining a percentage of each active element in a customized skin regimen is provided, in accordance with an embodiment.
  • Step 310 Obtain genetic statuses of one or more genomic locations related to a skin activity category from one or more samples obtained from a subject.
  • a skin activity category refers to a category related to activity in the skin, examples of which include one or more of an anti-aging and wrinkle reduction category, a lymphatic drainage category, a skin firming and elasticity category, a brightening and pigmentation category, a UV/oxidative damage/DNA/cell damage category, an anti-inflammatory and soothing category, and a hydration and skin barrier repair category.
  • determining a genetic issue can involve determining deficiency predispositions at the genetic level (e.g., single nucleotide polymorphisms (SNPs), or other genetic mutations). Genetic testing for predispositions can assist in providing information about a subject’s skin health. Table 4 provides exemplary skin-related polymorphisms that can be assessed and the polygenic risk associated with the polymorphisms. Genetic issues are medical or health problems that arise due to changes or mutations in an individual’s DNA. These changes can affect how genes function and can lead to a variety of conditions or predispositions to certain disease.
  • SNPs single nucleotide polymorphisms
  • the skin activity category is one of the seven categories described above.
  • the one or more samples can be blood, saliva, skin biopsy or any other samples obtained from the subject for checking changes or mutations in the individual’s DNA.
  • Step 320 Obtain methylation statuses of one or more genes related to the skin activity category. Similar to the mutation check for the genes related to the skin activity category, the methylation status for these genes can be also checked. This includes analyzing DNA from blood, saliva, buccal swabs, skin biopsy, urine samples, and the like using bisulfite conversion, sequencing, or methylation- specific PCR, pyrosequencing, among other possible methods. Based on the DNA analysis, the methylation patten for each gene related to the skin activity category can be determined, which can be used to determine the methylation score or methylation age for this skin activity category for the subject.
  • Step 330 Obtain an image captured of the subject’s skin and a questionnaire from the subject.
  • the image can be captured through different means and have different resolutions, but the resolutions should be high enough for phenotype evaluation.
  • the image should be captured without using decoration tools, so that the details on the skin should more accurately reflect the subject’s real condition.
  • the questionnaire includes questions related to skin activities from different aspects, and include at least one question related to the skin activity category disclosed herein.
  • the exemplary questions in the questionnaire can be find in Table 13.
  • Step 340 Determine a methylation score, a phenotype score, and a genotype score for the skin activity category for the subject using the one or more of genetic statuses, methylation statuses, and the image.
  • the methylation score or the methylation age for the skin activity category can be determined based on the methylation pattern of each gene in the category by using Equation (1) described earlier.
  • the phenotype score can be determined based on the image evaluation and information collected from the questionnaire. For example, a first point total may be obtained from the image evaluation and a second point total can be obtained from the questionnaire, as shown in Table 10.
  • Step 350 For each of one or more of the methylation score, phenotype score, and genotype score, determine a fixed value for each of the plurality of elements of the skin activity category using the corresponding score. Briefly, the determined methylation score, phenotype score, and genotype score each can be used to independently determine a desired amount or fixed value for each active element in the skin activity category. That is, based on the determined methylation score for the category, a desired amount of each active element can be determined to address methylation related concerns.
  • each active element can be determined again to address phenotype related concerns, and based on the determined genotype score, yet another desired amount of each active element can be determined to address genotype related concerns.
  • the exact amount of each active element determined from three different aspects may be different or the same.
  • Step 360 For each element of the plurality of elements, combine fixed values across the one or more of the methylation score, phenotype score, and genetic score to determine a percentage of the element to be included in the customized skin regimen. In other words, the exact amount of each active element determined from three different aspects in Step 350 can be combined to determine a percentage of the element to be included in the customized. In some embodiments, an average score is first computed based on the determined methylation score, phenotype score, and genetic score, which is then used to determine the percentage of the element to be included in the customized.
  • each active element can be determined for the exact amount to be included in the customized skin regime, which combined with the base elements can form a customized skin regimen for the subject, which can purposely address the concerns specific to the subject.
  • the customized skin regimen can comprise any active element provided in Tables 2, 3, 5, 6, 12, 14, 15, 16, 17, 21-1 to 21-9, or 22-1 to 22-9.
  • the skin care regimen comprises one or more topical or supplement selected from Tables 2, 3, 5, 6, 12, 14, 15, 16, 17, 21-1 to 21-9, or 22-1 to 22-9.
  • the skin care regimen comprises one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, fifteen or more, sixteen or more, seventeen or more, eighteen or more, nineteen or more, or twenty or more topical or supplement selected from Tables 2, 3, 5, 6, 12, 14, 15, 16, 17, 21-1 to 21-9, or 22-1 to 22-9.
  • Table 3 provides additional information about the topicals and/or supplements for use in the composition to be applied to improve skin health.
  • Provided in Table 3 is the name of the topical and supplement, an exemplary vendor, the sequence or chemical structure of the topicals and supplements, the CAS number, and if available, the INCI name.
  • compositions to be applied to improve skin health comprise one or more topicals and/or supplements based on presence of specific serological skin biomarkers.
  • the serological skin biomarker is the Amino terminal propeptide of Collagen 1 (PINP), and the composition comprises one or more of vitamin C, peptides, retinoids, copper peptides, copper, collagen or collagen peptides, and omega-3 fatty acids.
  • the serological skin biomarker is the Carboxy terminal propeptide of type 1 collagen (PICP) and the composition comprises one or more of hyaluronic acids, retinoids, vitamin C, niacinamide, collagen or collagen peptides, zinc, and omega-3 fatty acids.
  • the serological skin biomarker is the Crosslinked telopeptide of type 1 collagen (ICTP), and the composition comprises one or more of retinoids, vitamin C, peptides, proline, glycine, vitamin E, vitamin C, and copper.
  • the serological skin biomarker is the Amino terminal propeptide of Collagen 3 (PIIINP), and the composition comprises one or more of alpha hydroxy acids, retinoids, vitamin C, peptides, glycine, proline, and omega-3 fatty acids.
  • the serological skin biomarker is the Matrix metalloproteinases- 1 (MMP-1) and the composition comprises one or more of ginseng, green tea extract, retinoids, vitamin C, peptides, collagen or collagen peptides, vitamin E, vitamin C, and omega-3 fatty acids.
  • the serological skin biomarker is Insulin like growth factor- 1 (IGF-1) and the composition comprises one or more of capsaicin, vitamin C, hyaluronic acid, zinc, vitamin C, probiotics, collagen or collagen peptides, and omega-3 fatty acids.
  • the serological skin biomarker is Basic fibroblast growth factor (FGF-2) and the composition comprises one or more of ginseng, vitamin C, hyaluronic acid, collagen or collagen peptides, resveratrol, glycine, or proline.
  • the serological skin biomarker is Matrix Metalloproteinases- 12 (MMP-12) and the composition comprises one or more of vitamin C, green tea extract, silicon, ginseng, and vitamin E.
  • the serological skin biomarker is Elastin derived peptides (EDPs), and the composition comprises one or more of niacinamide, hyaluronic acid, silicon, vitamin A, and aloe vera.
  • one, two, three, four, five, six, seven, eight, nine, ten or more of the topical or supplementary compositions provided in Tables 2, 3, or 15 can be used in the skin care regimen compositions and methods described herein.
  • the composition comprises a topical skin care composition or medication.
  • topicals include, but are not limited to, vitamin C, peptides, retinoids, copper peptides, hyaluronic acid, niacinamide, alpha hydroxy acids (AHA), ginseng, green tea extract, and capsaicin.
  • the composition comprises a supplemental skin care composition.
  • Exemplary supplemental compositions include, but are not limited to, collagen and collagen peptides, vitamin C, omega-3 fatty acids, copper, zinc, omega-3 fatty acids, proline, glycine, vitamin E, curcumin, resveratrol, Eicosapentaenoic acid, Docosahexaenoic acid, vitamin D, probiotics, silicon, ginseng, aloe vera.
  • Peptides that can be used in the composition and method described herein are provided in Table 3.
  • the peptide is one or more of Hexapeptide- 11, GHK-Cu, Palmitoyl Pentapeptide-4 (Pal-KTTKS), Palmitoyl Tetrapeptide-7 (Pal-GQPR), Dipeptide-2, Palmitoyl Pentapeptide- 3, decapeptide- 12, Dipeptide Diaminobutyroyl Benzylamide Diacetate, Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine, Palmitoyl Dipeptide-5 Diaminohydroxybutyrate, Tetradecyl Aminobutyroylvalylaminobutyric Urea Trifluoroacetate, Acetyl Tetrapeptide-5, Heptapeptide-4, Acetyl Hexapeptide-51 Amide, Acetyl Hexapeptide-30, Acetyl Hexapeptide-
  • Retinoids that can be used in the composition and method described herein are provided in Table 3.
  • the retinoid is one or more of retinol, retinal, tretinoin (retinoic acid), isotretinoin, alitretinoin, adapalene, bexarotene, tazarotene, and/or Trifarotene.
  • Omega-3 fatty acids that can be used in the composition and method described herein are provided in Table 3.
  • the omega-3 fatty acid is one or more of Alpha-linolenic acid (ALA), Eicosapentaenoic acid (EPA), and/or Docosahexaenoic acid (DHA).
  • Alpha hydroxy acids that can be used in the composition and method described herein are provided in Table 3.
  • the Alpha hydroxy acid is one or more of glycolic acid, lactic acid, mandelic acid, and/or citric acid.
  • the topical and/or supplemental compositions can be formulated in an appropriate carrier or excipient.
  • exemplary carriers include, but are not limited to, water, Caprylyl Glycol, butylene glycol, ultra low molecular weight (ulmw) hyaluronic acid, middle molecular weight (MMW) hyaluronic acid, and dimethyl isosorbide.
  • Table 20 includes various base elements for the customized skin regime.
  • the base elements can include one or more of polymer/solubilizing/gelling/ emulsifier agents, one or more of humectant and emollient, one or more preservative, one or more chelating agent, one or more penetration enhancers, and one or more perfume.
  • the possible amounts or range for these base elements can be specified .
  • Table 21-1 to Table 21-9 further include possible active elements that can be added to the base elements for the score-based customized skin regime.
  • the active elements can include certain types of peptides, one or more prebiotics and probiotics and vitamins.
  • the peptides can be further categorized into seven different categories, namely, the anti-aging and wrinkle reduction category, the lymphatic drainage category, the skin firming and elasticity category, the brightening and pigmentation category, the UV/oxidative damage/DNA/cell damage category, the anti-inflammatory and soothing category, and the hydration and skin barrier repair category.
  • the specific sequence of each peptide and its respective function can be further located from Table 21-1 and Table 21-7.
  • palmitoyl hexapeptide- 12 (Biopeptide EL) has specific function of improving skin forming and elasticity, and thus can be added as the active element to the customized skin regimen to improve the skin forming and elasticity.
  • the supplement or topical can be formulated at an effective amount in the skin care regimen composition.
  • exemplary effective concentrations for active elements such as any active element disclosed in any of Tables 2, 3, 5, 6, 12, 14, 15, 16, 17, 21-1 to 21-9, or 22-1 to 22-9 can be 0.1-10% wt/vol or 0.1-10% wt/wt.
  • the concentration can be about 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% wt/vol or wt/wt.
  • Exemplary effective amounts of active elements can also be between about 0.5- 1500 mg/day.
  • effective amounts of any active element disclosed in any of Tables 2, 3, 5, 6, 12, 14, 15, 16, 17, 21-1 to 21-9, or 22-1 to 22-9 can be 0.5 mg/day, 1 mg/day, 2 mg/day, 3 mg/day, 4 mg/day, 5 mg/day, 6 mg/day, 7 mg/day, 8 mg/day, 9 mg/day, 10 mg/day, 20 mg/day, 25 mg/day, 30 mg/day, 35 mg/day, 40 mg/day, 45 mg/day, 50 mg/day, 55 mg/day, 60 mg/day, 65 mg/day, 70 mg/day, 75 mg/day, 80 mg/day, 85 mg/day, 90 mg/day, 95 mg/day, 100 mg/day, 110 mg/day, 120 mg/day, 130 mg/day, 140 mg/day, 150 mg/day, 160 mg/day, 170 mg/day, 180 mg/day, 190 mg/day, 200 mg/day
  • Exemplary effective amounts can also be between about 1-400 mcg/day, such as 1 mcg/day, 2 mcg/day, 2.4 mcg/day, 3 mcg/day, 4 mcg/day, 5 mcg/day, 6 mcg/day, 7 mcg/day, 8 mcg/day, 9 mcg/day, 10 mcg/day, 20 mcg/day, 25 mcg/day, 30 mcg/day, 35 mcg/day, 40 mcg/day, 45 mcg/day, 50 mcg/day, 55 mcg/day, 60 mcg/day, 65 mcg/day, 70 mcg/day, 75 mcg/day, 80 mcg/day, 85 mcg/day, 90 mcg/day, 95 mcg/day, 100 mcg/day, 110 mcg/day, 120
  • a computing device can include a personal computer, desktop computer laptop, server computer, a computing node within a cluster, message processors, hand-held devices, multiprocessor systems, microprocessor-based or programmable consumer electronics, network PCs, minicomputers, mainframe computers, mobile telephones, PDAs, tablets, pagers, routers, switches, and the like.
  • FIG. 4 illustrates an example computing device 400 for implementing system and methods described in FIGs. 1-3.
  • the computing device 400 includes at least one processor 402 coupled to a chipset 404.
  • the chipset 404 includes a memory controller hub 420 and an input/output (VO) controller hub 422.
  • a memory 406 and a graphics adapter 412 are coupled to the memory controller hub 620, and a display 418 is coupled to the graphics adapter 412.
  • a storage device 408, an input interface 414, and network adapter 416 are coupled to the VO controller hub 422.
  • Other embodiments of the computing device 400 have different architectures.
  • the storage device 408 is a non-transitory computer-readable storage medium such as a hard drive, compact disk read-only memory (CD-ROM), DVD, or a solid-state memory device.
  • the memory 406 holds instructions and data used by the processor 402.
  • the input interface 414 is a touch-screen interface, a mouse, track ball, or other type of input interface, a keyboard, or some combination thereof, and is used to input data into the computing device 400.
  • the computing device 400 may be configured to receive input (e.g., commands) from the input interface 414 via gestures from the user.
  • the graphics adapter 412 displays images and other information on the display 418.
  • the display 418 can show an indication of a treatment, such as a treatment validated by applying the cellular disease model.
  • the display 418 can show an indication of a common chemical structure group likely contributes toward an outcome (e.g., favorable outcome or adverse outcome).
  • the display 418 can show a candidate patient population that, through implementation of the cellular disease model, has been predicted to respond favorably to an intervention.
  • the network adapter 416 couples the computing device 400 to one or more computer networks.
  • the computing device 400 is adapted to execute computer program modules for providing functionality described herein.
  • module refers to computer program logic used to provide the specified functionality.
  • a module can be implemented in hardware, firmware, and/or software.
  • program modules are stored on the storage device 408, loaded into the memory 406, and executed by the processor 402.
  • a computing device 400 can include a processor 402 for executing instructions stored on a memory 406.
  • Embodiments of the methods described above can be implemented in computer programs executing on programmable computers, comprising a processor, a data storage system (including volatile and non-volatile memory and/or storage elements), a graphics adapter, an input interface, a network adapter, at least one input device, and at least one output device.
  • a display is coupled to the graphics adapter.
  • Program code is applied to input data to perform the functions described above and generate output information.
  • the output information is applied to one or more output devices, in known fashion.
  • the computer can be, for example, a personal computer, microcomputer, or workstation of conventional design.
  • Each program can be implemented in a high level procedural or object oriented programming language to communicate with a computer system.
  • the programs can be implemented in assembly or machine language, if desired. In any case, the language can be a compiled or interpreted language.
  • Each such computer program is preferably stored on a storage media or device (e.g., ROM or magnetic diskette) readable by a general or special purpose programmable computer, for configuring and operating the computer when the storage media or device is read by the computer to perform the procedures described herein.
  • the system can also be considered to be implemented as a computer-readable storage medium, configured with a computer program, where the storage medium so configured causes a computer to operate in a specific and predefined manner to perform the functions described herein.
  • the signature patterns and databases thereof can be provided in a variety of media to facilitate their use.
  • Media refers to a manufacture that contains the signature pattern information of the present invention.
  • the databases of the present invention can be recorded on computer readable media, e.g. any medium that can be read and accessed directly by a computer.
  • Such media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape; optical storage media such as CD-ROM; electrical storage media such as RAM and ROM; and hybrids of these categories such as magnetic/optical storage media.
  • magnetic storage media such as floppy discs, hard disc storage medium, and magnetic tape
  • optical storage media such as CD-ROM
  • electrical storage media such as RAM and ROM
  • hybrids of these categories such as magnetic/optical storage media.
  • Recorded refers to a process for storing information on computer readable medium, using any such methods as known in the art. Any convenient data storage structure can be chosen, based on the means used to access the stored information. A variety of data processor programs and formats can be used for storage, e.g. word processing text file, database format, etc.
  • a method for determining a customized skin regimen for a subject comprising: i.obtaining or having obtained levels of a plurality of skin biomarkers from one or more samples obtained from the subject; ii.obtaining or having genetic statuses of one or more genomic locations of a plurality of genes from the one or more samples obtained from the subject; and iii.determining the customized skin regimen for the subject using both the levels of the plurality of skin biomarkers and the genetic statuses of one or more genomic locations of a plurality of genes.
  • the skin biomarkers comprise one or more of collagens and elastins obtained from serum of the subject.
  • the collagen biomarkers comprise one or more of aminoterminal propeptide of Collagen 1 (PINP), carboxy-terminal propeptide of type 1 collagen (PICP), crosslinked telopeptide of type 1 collagen (ICTP), amino-terminal propeptide of collagen 3 (PIIINP), matrix metalloproteinases- 1 (MMP-1), tumor necrosis factor-alpha (TNF-a), insulin-like growth factor-1 (IGF-1), or basic fibroblast growth factor (FGF-2).
  • the elastin biomarkers comprise one or more of matrix metalloproteinases- 12 (MMP-12) or elastin-derived peptides (EDPs).
  • the serum is collected using one or more of ethylenediaminetetraacetic acid (EDTA), serum separator tube (SST), dried blood spot, or ficoll tube.
  • EDTA ethylenediaminetetraacetic acid
  • SST serum separator tube
  • dried blood spot or ficoll tube.
  • the levels of the plurality of skin biomarkers are obtained by using one or more of microarray or mass spectrometry.
  • the skin biomarkers comprise one or more lipids obtained from sebum of the subject.
  • the one or more lipids comprise one or more of glycerol lipids, free fatty acids, or cholesterol.
  • the skin biomarkers from the one or more samples obtained from the subject comprise skin biomarkers from urine of the subject.
  • the skin biomarkers from urine of the subject comprise one or more UV damage metabolites and oxidative stress loads from the urine of the subject.
  • the skin biomarkers comprise one or more advanced glycation end products from urine or blood of the subject.
  • the advanced glycation end products comprise one or more of carboxymethyl lysine (CEL), carboxymethyl lysine (CML), glucosepane, or pentosidine.
  • CEL carboxymethyl lysine
  • CML carboxymethyl lysine
  • glucosepane glucosepane
  • pentosidine pentosidine
  • the skin biomarkers comprise one or more microorganisms from skin niches of the subject.
  • the microorganisms comprise one or more of Propionibacterium acnes, Propionibacterium avidum, or Propionibacterium granulosum, optionally from forehead of the subject.
  • the microorganisms comprise Propionibacterium acnes, optionally from cheek of the subject.
  • the microorganisms comprise one or more of Staphylococcus epidermidis, Corynebacterium spp, or Propionibacterium acnes, optionally from nasolabial fold of the subject.
  • the microorganisms comprise Propionibacterium acnes, optionally from chin of the subject.
  • the microorganisms comprise Firmicutes, optionally from face of the subject.
  • the microorganisms comprise one or more of Corynebacterium kroppenstedtiin or Staphylococcus epidermidis, optionally from cheek of the subject.
  • the microorganisms comprise Corynebacterium kroppenstedtiin, optionally from nasolabial fold of the subject.
  • the microorganisms comprise Staphylococcus epidermidis, optionally from eyelid of the subject.
  • the microorganisms comprise Staphylococcus epidermidis, optionally from cheek of the subject.
  • the microorganisms comprise Corynebacterium species, optionally from chin of the subject.
  • the microorganisms comprise Malassezia spp, optionally from cheek of the subject.
  • the microorganisms comprise one or more Eikenella corrodens, Cutibacterium, Micrococcus luteus, or Kocuria, optionally from cheek of the subject.
  • the microorganisms comprise Acinetobacter, optionally from cheek of the subject.
  • the microorganisms comprise Corynebacterium, optionally from cheek of the subject.
  • the microorganisms comprise one or more of Corynebacterium amycolatum, Proteobacteria, Firmicutes, Bacteroidetes, or Propionibacterium, optionally from forehead of the subject.
  • the microorganisms comprise Propionibacterium, optionally from cheek of the subject.
  • the microorganisms comprise one or more of Corynebacterium, Lactobacillus, or Cutibacterium, optionally from face of the subject.
  • the skin biomarkers comprise one or more hormones from urine or blood of the subject.
  • the hormones comprise one or more of estrone (El), estradiol (E2), dehydroepiandrosterone (DHEA), testosterone, epitestosterone (Epi-T), androstenedione (AD), androsterone, etiocholanolone, 5-alpha- dihydrotestosterone (5a-DHT), dehydroepiandrosterone sulfate (DHEA-S), progesterone (P), cortisol, cortisone, b-tetrahydrocortisol (b-THF), a-Tetrahydrocortisol (a-THF), b- Tetrahydrocortisone (b-THE), deoxycorticosterone, corticosterone, melatonin, or 8-hydroxy- 2' -deoxyguanosine (8-OHdG).
  • estrone El
  • estradiol E2
  • DHEA dehydroepiandrosterone
  • obtaining the levels of a plurality of skin biomarkers further comprises determining one or more combinations of levels of the one or more hormones.
  • determining one or more combinations of levels of the one or more hormones comprises determining one or more of Estriol (E3)/(E1+E2), 2-OH (El + E2)/16a-OH El, 2-MeO E1/2-OH El, 4-MeO E1/4-OH El, 4-MeO E2/4-OH E2, testosterone (T)/Epi-T, b-pregnanediol/E2, cortisol/cortisone, or metabolized cortisol (THF+THE), or Prostaglandin (Pg)/E2.
  • the hormones comprise one or more of estrone (El), estradiol (E2), Estriol (E3), total estrogen, 2-OH estradiol, 2-OH estrone, 4-OH estradiol, 4-OH estrone, dehydroepiandrosterone (DHEA), androstenedione, androsterone, etiocholanolone, 5-alpha- dihydrotestosterone (5a-DHT), 5a, 3a- Androstanediol, 5P-Androstanediol, dehydroepiandrosterone sulfate (DHEA-S), progesterone, allopregnanolone, allopregnanediol, 3a-dihydroprogesterone, 20a- dihydroprogesterone, b-pregnanediol, a-pregnanediol, cortisol, cor
  • obtaining the levels of a plurality of skin biomarkers further comprises determining one or more combinations of levels of the one or more hormones.
  • determining one or more combinations of levels of the one or more hormones comprises determining one or more of E3/(E1+E2), 2-OH (El + E2)/16a- OH El, 2-MeO E1/2-OH El, 4-MeO E1/4-OH El, 4-MeO E2/4-OH E2, T/Epi-T, b- pregnanediol/E2, cortisol/cortisone, or metabolized cortisol (THF+THE), or Prostaglandin (Pg)/E2.
  • the skin biomarkers comprise one or more metabolism markers from serum or urine of the subject.
  • the metabolism markers comprise one or more serum metabolism biomarkers.
  • the serum metabolism biomarkers comprise one or more of lipid metabolism biomarkers, carbohydrate metabolism biomarkers, or cellular biomarkers.
  • the lipid metabolism biomarkers comprise one or more of vaccenic acid, adiponectin, acylhexosylceramide (AHC), diacylglycerol (DAG), dimethylphosphatidy lethanolamine (DMPE), or plasminogen activator inhibitor- 1 (PAI-1).
  • AHC acylhexosylceramide
  • DAG diacylglycerol
  • DMPE dimethylphosphatidy lethanolamine
  • PAI-1 plasminogen activator inhibitor- 1
  • the carbohydrate metabolism biomarkers comprise one or more of adiponectin, gastric-inhibitor-peptide (GIP), or leptin.
  • GIP gastric-inhibitor-peptide
  • the cellular biomarkers comprise nicotinamide adenine dinucleotide (NAD).
  • NAD nicotinamide adenine dinucleotide
  • the metabolism markers comprise one or more urine metabolism biomarkers.
  • the urine metabolism biomarkers comprise one or more of lipid metabolism biomarkers or carbohydrate metabolism biomarkers.
  • the lipid metabolism biomarkers comprise one or more of adipate, suberate, or ethyl malonate.
  • the carbohydrate metabolism biomarkers comprise one or more of pyruvate, L-lactate, or P-hydroxybutyrate.
  • the skin biomarkers comprise one or more nutrients from the subject.
  • the nutrients comprise one or more vitamins or minerals.
  • the vitamins or minerals comprise one or more of Folate
  • vitamin Bl thiamine diphosphate
  • vitamin B2 riboflavin 5-Phosphate
  • vitamin B5 pantothenic acid
  • vitamin B6 pyridoxal 5- Phosphate
  • vitamin C L-ascorbic acid
  • the nutrients comprise one or more vitamins and minerals, amino acids, or fatty acids.
  • the method further comprises further comprising determining one or more combinations of levels of one or more of the vitamins and minerals.
  • determining one or more combinations of levels of one or more of the vitamins and minerals further comprises obtaining a ratio of copper/zinc.
  • the amino acids comprise one or more of glutathione (oxidized), methylmalonic acid (MMA), choline, L-cysteine, L-asparagine, L-glutamine, L- serine, L-arginine, L-citrulline, L-isoleucine, L-valine, L-leucine, free carnitine, or phenylalanine.
  • the fatty acids comprise one or more of docosahexaenoic acid (DHA), Eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), arachidonic acid (AA), or linoleic acid (LA).
  • DHA docosahexaenoic acid
  • EPA Eicosapentaenoic acid
  • DPA docosapentaenoic acid
  • AA arachidonic acid
  • LA linoleic acid
  • the method further comprises obtaining the levels of a plurality of skin biomarkers by determining one or more combinations of levels of one or more of the fatty acids.
  • determining one or more combinations of levels of one or more of the fatty acids further comprises obtaining omega-3 total, omega-6 total, omega-3 index, or a ratio of AA/EPA.
  • the skin biomarkers comprise one or more commensal microorganisms from the subject.
  • the commensal microorganisms comprise one or more of commensal bacteria, archaea, fungi, or viruses.
  • the skin biomarkers further comprise gut metabolites from the subject.
  • the method further comprises obtaining or having obtained one or more demographics of the subject; and determining the customized skin regimen for the subject based on the demographics of the subject.
  • the demographics comprise one or more of an age or gender of the subject.
  • the method further comprises: iv. obtaining or having obtained an image of a face from the subject; v. grading severities of one or more phenotypic parameters for the face of the subject based on the image; and vi. determining the customized skin regimen for the subject based on the severity of the one or more phenotypic parameters.
  • the phenotypic parameters comprise one or more of wrinkles, periorbital- around eyes (puffy eyes), nasolabial folds (laugh lines), worry lines, uneven skin tone/pigmentation, or age spots (liver spots).
  • the method further comprises obtaining or having obtained answers to a skin questionnaire from the subject; and determining the customized skin regimen for the subject based on the answers from the subject.
  • the questionnaire comprises one or more questions related to skin goals, type of skin, sun exposure, or skin proneness to external factors.
  • the method further comprises administering the customized skin regimen to the subject.
  • the customized skin regimen can be applied topically to the skin of the subject.
  • customized skin regimens wherein the customized skin regimen is determined according to a method disclosed herein.
  • a skin biomarker is the Amino terminal propeptide of Collagen 1 (PINP), and the composition comprises one or more of vitamin C, peptides, retinoids, copper peptides, copper, collagen or collagen peptides, and/or omega-3 fatty acids;
  • a skin biomarker is the Carboxy terminal propeptide of type 1 collagen (PICP) and the composition comprises one or more of hyaluronic acids, retinoids, vitamin C, niacinamide, collagen or collagen peptides, zinc, and/or omega-3 fatty acids; iii.
  • a skin biomarker is the Crosslinked telopeptide of type 1 collagen (ICTP), and the composition comprises one or more of retinoids, vitamin C, peptides, proline, glycine, vitamin E, vitamin C, and/or copper;
  • a serological skin biomarker is the Amino terminal propeptide of Collagen 3 (PIIINP), and the composition comprises one or more of alpha hydroxy acids, retinoids, vitamin C, peptides, glycine, proline, and/or omega-3 fatty acids;
  • a skin biomarker is the Matrix metalloproteinase- 1 (MMP-1) and composition comprises one or more of ginseng, green tea extract, retinoids, vitamin C, peptides, collagen or collagen peptides, vitamin E, vitamin C, and/or omega-3 fatty acids;
  • a skin biomarker is Insulin like growth factor- 1 (IGF-1) and the composition comprises one or more of capsaicin, vitamin C, hyaluronic acid, zinc, vitamin C, probiotics, collagen or collagen peptides, and/or omega-3 fatty acids; vii.
  • a skin biomarker is Basic fibroblast growth factor (FGF-2) and the composition comprises one or more of ginseng, vitamin C, hyaluronic acid, collagen or collagen peptides, resveratrol, glycine, and/or proline; viii. a skin biomarker is Matrix Metalloproteinase- 12 (MMP-12) and the composition comprises one or more of vitamin C, green tea extract, silicon, ginseng, and/or vitamin E; ix. a skin biomarker is Elastin derived peptides (EDPs), and the composition comprises one or more of niacinamide, hyaluronic acid, silicon, vitamin A, and/or aloe vera.
  • FGF-2 Basic fibroblast growth factor
  • FGF-2 Basic fibroblast growth factor
  • the composition comprises one or more of ginseng, vitamin C, hyaluronic acid, collagen or collagen peptides, resveratrol, glycine, and/or proline
  • the peptide is one or more of Hexapeptide- 11, GHK-Cu, Palmitoyl Pentapeptide-4 (Pal-KTTKS), Palmitoyl Tetrapeptide-7 (Pal-GQPR), Dipeptide-2, Palmitoyl Pentapeptide- 3, decapeptide- 12, Dipeptide Diaminobutyroyl Benzylamide Diacetate, Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine, Palmitoyl Dipeptide-5 Diaminohydroxybutyrate, Tetradecyl Aminobutyroylvalylaminobutyric Urea Trifluoroacetate, Acetyl Tetrapeptide-5, Heptapeptide-4, Acetyl Hexapeptide-51 Amide, Acetyl Hexapeptide-30, Acetyl Hexapeptide-8 (Argireline), acetyl hexapeptide-3 (Argireline), Acetyl
  • the retinoid is one or more of retinol, retinal, tretinoin (retinoic acid), isotretinoin, alitretinoin, adapalene, bexarotene, tazarotene, and/or Trifarotene.
  • the omega-3 fatty acid is one or more of Alpha-linolenic acid (ALA), Eicosapentaenoic acid (EPA), and/or Docosahexaenoic acid (DHA).
  • ALA Alpha-linolenic acid
  • EPA Eicosapentaenoic acid
  • DHA Docosahexaenoic acid
  • the Alpha hydroxy acid is one or more of glycolic acid, lactic acid, mandelic acid, and/or citric acid.
  • a polymorphism is a SNP associated with melanin synthesis and the composition comprises one or more of Hydroquinone, Retinoids, Azelaic acid, Kojic acid, Cysteamine, Lignin peroxidase, Niacinamide, Ellagic acid, L- Cystine, L-Glutathione, Polypodium leucotomos, Melatonin, Arbutin, and/or Vitamin C; ii.
  • a polymorphism is a SNP associated with Moisturization and the composition comprises one or more of Vitamin E, Coenzyme Q10, Vitamin F, Kumazasa extract, Magnesium ascorbyl phosphate, Hyaluronic acid, Magnesium oil, collagen, ceramides, hyaluronan, procyanidin, probiotics, Galactooligosaccharides, Alpha-linolenic acid, and/or Gamma-linolenic acid; iii.
  • a polymorphism is a SNP associated with Skin Inflammation and the composition comprises one or more of Coenzyme Q10, Methylsulfonylmethane, Retinoid, Vitamin E, Vitamin C, Curcumin, Green tea or green tea extract, and/or Omega 3 fatty acids;
  • apolymorphism is a SNP associated with Melanocyte damage and the composition comprises one or more of Coenzyme Q10, Methylsulfonylmethane, Retinoid, Vitamin E, Vitamin D, Zinc, Vitamin C, Curcumin, Green tea or green tea extract, and/or Omega 3 fatty acids;
  • a polymorphism is a SNP associated with Collagen degradation and the composition comprises one or more of Retinoids, Vitamin C, Vitamin E, Tretinoin, Collagen peptides, Red ginseng, Aloe vera extract, Hyaluronic acid, Ginkgo biloba, and/or Soy; vi. a polymorphism is a SNP associated with Elastin synthesis and the composition comprises one or more of Retinoid, Vitamin C, Collagen or collagen peptides, Hyaluronic acid, Dexpanthenol, Vitamin E, Vitamin A, and/or Zinc; vii.
  • a polymorphism is a SNP associated with Antioxidants and the composition comprises one or more of Vitamin C, Coenzyme Q10, Polyphenols, Vitamin E, Curcumin, Vitamin C, Vitamin E, Beta carotene, Flavanols, zinc, Lutein, Lycopene, Silymarin, and/or Green tea or green tea extract; viii.
  • a polymorphism is a SNP associated with Vitamin A deficiency and the composition comprises one or more of Retinol, Vitamin E, Resveratrol, Baicalin, B-vitamins, Vitamin C, Epigallocatechin gallate, Collagen, Nicotinamide riboside, Nicotinamide mononucleotide, Coenzyme Q10, and/or Curcumin; ix.
  • a polymorphism is a SNP associated with Vitamin B6 deficiency and the composition comprises one or more of B-vitamins, Vitamin B6, Coenzyme Q10, Methylsulfonylmethane; Retinoids, and Vitamin E, Curcumin, Green tea or green tea extract, Omega 3 fatty acids, and/or Vitamin C; x.
  • a polymorphism is a SNP associated with Vitamin B 12 deficiency and the composition comprises one or more of Retinol, Vitamin E, Resveratrol, Baicalin, B-vitamins, Vitamin B12, Vitamin C, Curcumin, Epigallocatechin gallate, Collagen, Nicotinamide riboside, Nicotinamide mononucleotide, and/or Coenzyme Q10,; xi.
  • a polymorphism is a SNP associated with Vitamin C deficiency and the composition comprises one or more of Vitamin C, Coenzyme Q10, Polyphenols, Vitamin E, Curcumin, Beta carotene, Flavanols, zinc, Lutein, Lycopene, Silymarin, and/or Green tea or green tea extract; xii.
  • a polymorphism is a SNP associated with Vitamin D deficiency and the composition comprises one or more of Vitamin D, Retinol, Vitamin E, Resveratrol, Baicalin, B-vitamins, Vitamin C, Curcumin, Epigallocatechin gallate, Collagen, Nicotinamide riboside, Nicotinamide mononucleotide, and/or Coenzyme Q10; xiii.
  • a polymorphism is a SNP associated with Folate deficiency and the composition comprises one or more of Folate, Retinol, Vitamin E, Resveratrol, Baicalin, B-vitamins, Vitamin C, Curcumin, Epigallocatechin gallate, Collagen, Nicotinamide riboside, Nicotinamide mononucleotide, and Coenzyme Q10; and/or xiv.
  • a polymorphism is a SNP associated with Omega fatty acid deficiency and the composition comprises one or more of DHA (Docosahexaenoic acid), EPA, Coenzyme Al, Methylsulfonylmethane, Retinoid, Curcumin, Green tea or green tea extract and/or Vitamin E.
  • DHA Docosahexaenoic acid
  • EPA Docosahexaenoic acid
  • Coenzyme Al Methylsulfonylmethane
  • Retinoid Curcumin
  • Curcumin Green tea or green tea extract and/or Vitamin E.
  • a phenotypic parameter is wrinkles, Periorbital- around eyes (puffy eyes), Nasolabial folds (Laugh lines), worry lines, Uneven Skin tone/Pigmentation, and/or Age spots (Liver spots) and the composition comprises one or more of Tretinoin, Zeaxanthin, Retinol, Retinoids, Vitamin C, Hyaluronic acid, Caffeine, Phytonadione, Vitamin E, Astaxanthin, Hyaluronic acid, Peptides, Niacinamide, Azelaic acid, Soybean extract, Kojic acid, Aloesin, and/or Turmeric.
  • the customized skin regimen further comprises one or more of Zeaxanthin, Collagen, Vitamin C, Resveratrol, Vitamin E, Vitamin C, Hyaluronic acid, Glutathione, Niacinamide, and/or Coenzyme Q10.
  • a skin questionnaire question is: i. UV and the composition comprises one or more of Zinc oxide, titanium oxide, Polypodium leucotomos, Vitamin E, Vitamin C, and/or Niacinamide; ii. Anti-wrinkling and the composition comprises one or more of Tretinoin, Zeaxanthin, Retinol, Vitamin C, Hyaluronic acid, Collagen, Resveratrol, and/or Vitamin E; iii. Anti-pigmentation and the composition comprises one or more of Niacinamide, Azelaic acid, Vitamin C, Soybean extract, Retinoids, Kojic acid, Vitamin E, Aloesin, Turmeric, and/or Glutathione iv.
  • Moisturization and the composition comprises one or more of Hyaluronic acid, Glycerin, Shea butter, Jojoba oil, Hyaluronan, Ceramides, and Collagen; v. Radiant complexion and the composition comprises one or more of Vitamin C and/or Niacinamide, vi. Dry skin and the composition comprises Glycerin; vii. Combinational skin and the composition comprises Hyaluronic acid; viii. Acne-prone skin and the composition comprises Benzoyl peroxide; ix. Sun exposure and the composition comprises Zinc oxide and/or Titanium dioxide; x. Sensitive skin - stinging or burning and the composition comprises Niacinamide xi.
  • a hormone is: i. one or more of estrone (El), estradiol (E2), dehydroepiandrosterone (DHEA), testosterone, epi-testosterone (Epi-T), androstenedione (AD), androsterone, etiocholanolone, 5-alpha- dihydrotestosterone (5a-DHT), dehydroepiandrosterone sulfate (DHEA-S), progesterone (P), cortisol, cortisone, b-tetrahydrocortisol (b-THF), a-Tetrahydrocortisol (a-THF), b- Tetrahydrocortisone (b-THE), deoxycorticosterone, corticosterone, melatonin, or 8-hydroxy-2' -deoxyguanosine (8-OHdG); or ii.
  • estrone El
  • estradiol E2
  • DHEA dehydr
  • estrone El
  • estradiol E2
  • Estriol E3
  • total estrogen 2-OH estradiol
  • 2-OH estrone 4-OH estradiol
  • 4-OH estrone 4-OH estrone
  • dehydroepiandrosterone DHEA
  • etiocholanolone 5-alpha- dihydrotestosterone
  • 5a-DHT 5-alpha- dihydrotestosterone
  • DHEA- S dehydroepiandrosterone
  • progesterone progesterone
  • allopregnanolone allopregnanediol
  • 3a-dihydroprogesterone 20a-dihydroprogesterone
  • b-pregnanediol a-pregnanediol
  • cortisol cortisone
  • b-tetrahydrocortisol b-THF
  • the composition comprises one or more of Calcium D-glucarate, Green Tea, Maca DIM (3,3'-diindolylmethane), Black Cohosh, Ginger, Cranberry, Milk Thistle, Hops, Red clover, Damiana, Chaste Tree Berry Extract, Vitamin B2, Fenugreek seed, Ashwagandha, Vitamin D3, Zinc, Tribulus, Shatavari, Zinc, Shatavari, DHA, EPA, pine nuts, Licorice Root Extract, Oregano, Curcumin, Sodium, Rhodiola rosea, Vitamin B6, Vitamin B12, Magnesium, Folate, Iodine, Selenium, Potassium, Magnesium, Melatonin, Huang-qin, St. John's- wort, SAMe (S-adenosyl methionine), and/or Trimethylglycine (betaine).
  • Calcium D-glucarate Green Tea
  • Maca DIM 3,3'-diindolylmethane
  • a metabolic biomarker is one or more of Vaccenic acid, Adiponectin, Acylhexosylceramide (AHC), Dimethyl-phosphatidylethanolamine (DMPE), PAI-1, GIP, Leptin, NAD, Adipate, Suberate, Ethyl malonate, Pyruvate, L-lactate, and/or P- hydroxybutyrate and the supplemental or topical is one or more of Conjugated Linoleic Acid, DHA, EPA, Vitamin D, Curcumin, Berberine Extract, Resveratrol, Vitamin B3, Vitamin B6, Vitamin E, Choline, Vitamin C, Tryptophan, Nicotinamide riboside, Resveratrol, Quercetin, Vitamin B2, L-camitine, Vitamin Bl, Vitamin B12, CoQlO (Coenzyme Q10), Alpha lipoic acid, and/or Chromium.
  • Conjugated Linoleic Acid DHA, EPA, Vitamin D, Curcumin, Ber
  • customized skin regimens wherein the customized skin regimen comprises one or more supplement or topical medication, or a supplement and a topical medication.
  • the one or more topical medication and/or supplement comprise one or more of B-vitamins, Vitamin Bl, Vitamin B2, Vitamin B3, Vitamin B6, Vitamin B12, vitamin C, vitamin D, vitamin E, vitamin F, peptides, retinoids, copper peptides, copper, zinc, collagen or collagen peptides, omega-3 fatty acids, hyaluronic acids, niacinamide, zinc, proline, glycine, vitamin E, alpha hydroxy acids, ginseng, green tea or green tea extract, capsaicin, zinc, probiotics, resveratrol, glycine, proline, green tea or green tea extract, silicon, niacinamide, silicon, vitamin A, aloe vera, Hydroquinone, Azelaic acid, Kojic acid, Cysteamine, Lignin peroxidase, Ellagic acid, L-Cystine, L-Glutathione, Polypodium leucotomos, Melatonin
  • the peptide is one or more of Hexapeptide- 11, GHK-Cu, Palmitoyl Pentapeptide-4 (Pal-KTTKS), Palmitoyl Tetrapeptide-7 (Pal-GQPR), Dipeptide-2, Palmitoyl Pentapeptide- 3, decapeptide- 12, Dipeptide Diaminobutyroyl Benzylamide Diacetate, Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine, Palmitoyl Dipeptide-5 Diaminohydroxybutyrate, Tetradecyl Aminobutyroylvalylaminobutyric Urea Trifluoroacetate, Acetyl Tetrapeptide-5, Heptapeptide-4, Acetyl Hexapeptide-51 Amide, Acetyl Hexapeptide-30, Acetyl Hexapeptide-8 (Argireline), acetyl hexapeptide-3 (Argireline), Acetyl
  • the retinoid is one or more of retinol, retinal, tretinoin (retinoic acid), isotretinoin, alitretinoin, adapalene, bexarotene, tazarotene, and/or Trifarotene.
  • the omega-3 fatty acid is one or more of Alpha-linolenic acid (ALA), Eicosapentaenoic acid (EPA), and/or Docosahexaenoic acid (DHA).
  • ALA Alpha-linolenic acid
  • EPA Eicosapentaenoic acid
  • DHA Docosahexaenoic acid
  • the Alpha hydroxy acid is one or more of glycolic acid, lactic acid, mandelic acid, and/or citric acid.
  • the customized skin regimen further comprises an excipient or carrier.
  • Example 1 Calculating a Customized Skin Regimen for an Individual
  • Table 22-1 is utilized to illustrate the calculation of an amount of an active element in the anti-aging and wrinkle reduction category, to be included in the customized skin regime.
  • three scores were calculated including genotype score (referred to as “genotype”), methylation score (referred to as “methylation age”), and phenotype score (referred to as “phenotype age”).
  • the methylation score for the category was calculated by analyzing methylation patterns in the genes in Table 7 labelled as “anti-aging and wrinkle reduction” (e.g., CDKN2A, COL1A1, MMP1, SIRT1). Associated weights were assigned to each of the genes as shown in Table 7, and the methylation age (or methylation score) was calculated as the sum of the methylation level of each of the genes, weighted by the corresponding weights.
  • the phenotype score for the category was calculated by capturing images of the individual’s face, and by manually annotating the image for anti-aging and wrinkle reduction. A first point total for anti-aging and wrinkle reduction was assigned based on the annotated image (between 1-10 as shown in Table 10).
  • a second point total was assigned for anti-aging and wrinkle reduction based on the patient questionnaire (between 0-3 for this category, or 0-6 or 0-8 for other categories as shown in Table 10). Specific questions and the points assigned are shown in Table 13.
  • the first and second point totals were combined and phenotype age was assigned according to the combined points. Specifically, according to Table 11, the points range and corresponding phenotype age are shown. In general, the higher the combined point total, the larger the corresponding age for each category, although the specific point range for each phenotype age for each category may be different.
  • the genotype score, methylation age, and phenotype age were used to determine corresponding fixed values for each of the anti-aging and wrinkle reduction elements.
  • Table 22-1 Here, at least 1 genetic issue was identified for the genes included in this category, leading to the corresponding fixed values shown for each of the elements (e.g., 0.50% for palmitoyl pentapeptide-3 (Matrixyl), and so on). Additionally, the individual was determined to have a methylation age of 51-60, leading to corresponding fixed values shown in Table 22-1 for each of the elements (e.g., 2% for palmitoyl pentapeptide-3 (Matrixyl), and so on).
  • the individual was determined to have a phenotype age of 41-50, leading to corresponding fixed values shown in Table 22-1 for each of the elements (e.g., 2% for palmitoyl pentapeptide-3 (Matrixyl), and so on).
  • the average score for each element was determined. Specifically, for each element, the percentages were combined across the genotype score, the methylation age, and the phenotype age to generate an average score, as described earlier. For example, for palmitoyl pentapeptide-3 (Matrixyl), the average score is calculated as:
  • the average score was scaled to determine the final percentage of eah element, included in the category, to be added to the customized skin regime.
  • the scaling value for palmitoyl pentapeptide-3 (Matrixyl) was 60/80 and therefore, the final scaled percentage was calculated as:
  • Palmitoyl Pentapeptide- 3 (Matrixyl) was included in the customized skin regimen at 1.9% wt/wt%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Sont divulguées des méthodes pour fournir un régime cutané personnalisé à un individu en fonction du niveau de biomarqueurs cutanés et de statuts génétiques. Le régime cutané comprend des suggestions pour l'individu au moins de produits topiques, de compléments et/ou de changements de mode de vie.
PCT/US2024/053891 2023-10-31 2024-10-31 Méthodes et compositions pour fournir des régimes cutanés personnalisés Pending WO2025096781A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363546671P 2023-10-31 2023-10-31
US63/546,671 2023-10-31

Publications (2)

Publication Number Publication Date
WO2025096781A1 true WO2025096781A1 (fr) 2025-05-08
WO2025096781A8 WO2025096781A8 (fr) 2025-07-31

Family

ID=95581588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/053891 Pending WO2025096781A1 (fr) 2023-10-31 2024-10-31 Méthodes et compositions pour fournir des régimes cutanés personnalisés

Country Status (1)

Country Link
WO (1) WO2025096781A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160068904A1 (en) * 2013-04-24 2016-03-10 Skinshift Methods of skin analysis and uses thereof
US20180254102A1 (en) * 2013-11-14 2018-09-06 Mores, Inc. Method and Apparatus for Enhanced Personal Care
US20210164993A1 (en) * 2015-11-10 2021-06-03 Pathway Skin, Inc. Methods and Systems for Improving Skin Condition
US20210324480A1 (en) * 2017-04-10 2021-10-21 Dermtech, Inc. Non-invasive skin-based detection methods
US20230335288A1 (en) * 2018-01-29 2023-10-19 Function, Inc. Systems and methods for formulating personalized skincare products

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160068904A1 (en) * 2013-04-24 2016-03-10 Skinshift Methods of skin analysis and uses thereof
US20180254102A1 (en) * 2013-11-14 2018-09-06 Mores, Inc. Method and Apparatus for Enhanced Personal Care
US20210164993A1 (en) * 2015-11-10 2021-06-03 Pathway Skin, Inc. Methods and Systems for Improving Skin Condition
US20210324480A1 (en) * 2017-04-10 2021-10-21 Dermtech, Inc. Non-invasive skin-based detection methods
US20230335288A1 (en) * 2018-01-29 2023-10-19 Function, Inc. Systems and methods for formulating personalized skincare products

Also Published As

Publication number Publication date
WO2025096781A8 (fr) 2025-07-31

Similar Documents

Publication Publication Date Title
Li et al. New insights into the skin microbial communities and skin aging
Tuchayi et al. Acne vulgaris
Han et al. Differences in the gut microbiome and reduced fecal butyrate in elders with low skeletal muscle mass
Dréno et al. Nonprescription acne vulgaris treatments: Their role in our treatment armamentarium—An international panel discussion
Bissett et al. Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin 1
Jernerén et al. Brain atrophy in cognitively impaired elderly: The importance of long-chain ω-3 fatty acids and b vitamin status in a randomized controlled trial12
Webster et al. Clinical reviewAcne vulgarisCommentary: A UK primary care perspective on treating acne
Makrantonaki et al. Genetics and skin aging
Ma et al. Sensitive scalp is associated with excessive sebum and perturbed microbiome
Kang et al. A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage
Chien et al. Perioral wrinkles are associated with female gender, aging, and smoking: Development of a gender-specific photonumeric scale
McCook Topical products for the aging face
Berson et al. Niacinamide
US20090246153A1 (en) Cosmetic compositions for the inhibition of reactive oxygen species
Lee et al. Effects of repetitive superficial chemical peels on facial sebum secretion in acne patients
Gibson et al. Beneficial Effects of Multi-Micronutrient Supplementation with Collagen Peptides on Global Wrinkles, Skin Elasticity and Appearance in Healthy Female Subjects
Strauss et al. Concomitant administration of vitamin E does not change the side effects of isotretinoin as used in acne vulgaris: a randomized trial
Kim et al. Increased skin irritation by hydroquinone and rsetinoic acid used in combination
Levesque et al. Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne
WO2025096781A1 (fr) Méthodes et compositions pour fournir des régimes cutanés personnalisés
Pettigrew et al. Assessment of pre-and post-methionine load homocysteine for prediction of recurrent stroke and coronary artery disease in the Vitamin Intervention for Stroke Prevention Trial
Fang et al. Mitigation of retinol‐induced skin irritation by physiologic lipids: Evidence from patch testing
Shi et al. Investigating the impact of oral probiotic supplementation for acne management: A randomized controlled trial.
Gui et al. Decoding the anti-aging effect of retinol in reshaping the human skin microbiome niches
JP2024526110A (ja) 皮膚バリアを改善するための組成物および方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24886889

Country of ref document: EP

Kind code of ref document: A1